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Subunit vaccines rely on adjuvants to drive an immune response against antigens of interest. 
Improved adjuvant platforms, capable of interaction with specific pathogen recognition receptors 
in the innate immune system, can lead to more effective and longer lasting vaccines. 
Recombinant outer membrane vesicles (rOMVs) are a recently developed adjuvant system that 
harnesses the natural pathogen associated molecular patterns present in the outer membrane of E. 
coli to direct an immune response against recombinant antigens displayed on the rOMV surface. 
Though rOMV vaccines have demonstrated promise against viral antigens in murine models, 
their high lipopolysaccharide (LPS) content hinders translation to humans. This dissertation will 
present ways in which the LPS in rOMVs can be modified, through use of ‘detoxified’ 
commercial E. coli strains, as well as through genetic manipulation of probiotic E. coli strains, to 
generate rOMVs with greatly improved safety profiles. Additionally, it will profile the 
development of a potential pandemic influenza vaccine using detoxified rOMVs, demonstrating 
their feasibility in achieving protective immune responses.  
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1 
CHAPTER 1 
INTRODUCTION 
Adjuvants: a critical component to many vaccines 
Vaccines represent one of the most successful public health interventions in prevention of 
disease.  Through vaccination, smallpox has been completely eradicated, and great progress has 
been made towards the elimination polio and tetanus1,2.  More recently, vaccines against human 
papilloma virus (HPV) have already led to significantly fewer high grade cervical lesions3.   
While vaccines against certain pathogens have resulted in great success and high levels of 
protection, vaccines for other diseases remain elusive; highly effective vaccines against human 
immunodeficiency virus (HIV), malaria, influenza, and many others remain to be developed4.      
Currently, most vaccines can be roughly divided into the categories of live attenuated, 
inactivated, or subunit.  Live-attenuated vaccines are often generated via passage of the pathogen 
through a non-human cell type, causing the pathogen to become less adept at infecting human 
cells.  For example, to create the chickenpox vaccine, varicella zoster virus was passaged 
numerous times through guinea-pig embryo cultures5.   Inactivated vaccines are created by 
killing/inactivating the pathogen, preventing it from being infectious.  VAQTA, a hepatitis A 
vaccine produced by Merck, is comprised of formalin inactivated hepatitis A virus.  Subunit 
vaccines are made by using only select components of the pathogen, typically proteins6,7.  For 
example, the hepatitis B vaccine contains only the protein hepatitis B surface antigen (HBsAg), 
which is produced using yeast.  Historically, vaccines were made primarily via attenuation or 
inactivation; however, both of these strategies require working with large amounts of pathogen8.   
Additionally, attenuated vaccines, while often the longest lasting, can have drawbacks of being 
unable to be administered to immune-compromised individuals, reliance on refrigeration, and—
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in extremely rare cases—reversion to a more pathogenic form.   Inactivated vaccines are 
generally safer than attenuated vaccines, and can be given to immune compromised individuals.  
However, they typically require multiple doses to elicit long-term effects.  Additionally, 
producing inactivated pathogens for vaccines can be costly; the attenuated oral polio vaccine 
costs ~20x less per dose than the inactivated polio vaccine9.  Subunit vaccines offer the 
advantage of only requiring antigens from pathogens, which can be expressed using recombinant 
DNA techniques in non-pathogenic organisms, such as lab strains of Escherichia coli (E. coli)10.  
These pathogen-derived antigens are often poorly or non-immunogenic, and thus require addition 
of an adjuvant to elicit a sufficient immune response11.   
Adjuvants, immune response ‘helpers,’ are common additions in inactivated vaccines and 
are almost always found in subunit vaccines12.  Vaccines work by tricking the body into 
responding as if it were exposed to the actual pathogen.  Thus, the immune system responds by 
making neutralizing antibodies against the vaccine antigen, just as it would a true pathogen.  
When the actual pathogen invades, vaccination-induced antibodies neutralize the pathogen, 
preventing infection.  Pathogens contain conserved pathogen associated molecular patterns 
(PAMPs) that send danger signals to the immune system upon infection13.   Because of this, 
attenuated vaccines rarely require addition of adjuvant, as the live pathogen in the vaccine is able 
to produce sufficient danger signals.  Though inactivated vaccines are derived from a whole 
pathogen, the treatments to inactivate the pathogen, as well as its lack of infectivity, can reduce 
the number of PAMPs it contains.  Thus, inactivated vaccines sometimes require addition of an 
adjuvant to supply extra danger signals and to generate a more potent immune response14. 
Adding adjuvants to inactivated vaccines also allows for dose sparing, making it so that less of 
the expensive inactivated pathogen is necessary to achieve the same level of protective response.  
 	  
	  
3 
Subunit vaccines, because they only contain select antigens from pathogens, require adjuvants to 
supply danger signals15.  Thus, both the vaccine antigen and the vaccine adjuvant are important; 
antigen selection determines what the immune system targets and adjuvant selection shapes the 
type of response against that antigen. The most common vaccine adjuvants—and until 2009 the 
only adjuvants found in Food and Drug Administration (FDA) approved vaccines—are 
aluminum salts, or alum16.  Though the mechanisms of how alum elicits danger signals are still 
poorly understood, alum has nonetheless proven to be effective at strengthening the immune 
response and is contained in many vaccines17,18.   Adding alum to vaccines causes development 
of a broader antibody repertoire following vaccination and increases the affinity of antibodies 
that are produced.  Though alum is a useful adjuvant, developing adjuvants that more closely 
mimic the stimulation patterns of actual pathogens could lead to improved vaccine design19–21.   
Increased understanding of the innate immune system has led to a better understanding of 
pathogen recognition receptors (PRRs) in the innate immune system.  PAMPS on pathogens 
stimulate different patterns of PRRs, leading to varied immune responses22.  While most 
vaccines work primarily through eliciting neutralizing antibodies against an antigen, actual 
pathogens are cleared by both an antibody-based humoral response, as well as by a cellular 
response.  There are many nuances associated with immune responses, but the body often 
responds to intracellular pathogen invasion by developing a T helper cell 1 (Th1) biased 
response23.  When instead the body is infected with a parasite or affected by allergens, a Th2 
biased response is more common.  Th1 responses are characterized by a proinflammatory 
response, with high levels of IFNγ production.  Th1 cells indirectly lead to activation of CD8+ T 
cells (cytotoxic T cells), which can then kill infected cells. Th1 cells also lead to activation of B 
cells, which ultimately differentiate into plasma cells and produce IgG antibodies that can both 
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neutralize pathogens and clear infected cells via antibody dependent cellular cytotoxicity 
(ADCC) and antibody mediated phagocytosis (AMP)24,25. While alum is able to elicit IgG 
neutralizing antibodies, the antibodies are not always able to elicit ADCC and AMP.  In mice, 
IgG isotypes IgG2a and IgG2c (different mouse strains produce either IgG2a or IgG2c) contain 
Fc regions that interact with Fc receptors (FcR) on natural killer (NK) cells and macrophages, 
facilitating AMP and ADCC26.  However, alum typically leads to higher levels of IgG1 than 
IgG2a/IgG2c, which can neutralize a pathogen, but does not trigger AMP and ADCC.  
Additionally, while vaccines using alum as an adjuvant can elicit B cell responses, they typically 
do not elicit cytotoxic T cell responses27.  Creating vaccine adjuvants that elicit a Th1 biased 
response, complete with IgG2a or IgG2c antibodies and cytotoxic T cells, should help to create 
more effective vaccines that do a better job at preventing and clearing pathogen infection.  
Possibly, the lack of effective vaccines for certain diseases is due not to poor antigen selection, 
but rather to an ineffective immune response being mounted against that antigen.   
Recently, the FDA has approved vaccines with more diverse adjuvants28.  In 2009, 
Cervarix, a vaccine against cervical cancer produced by GlaxoSmithKline, received FDA 
approval29.  Cervarix is comprised of proteins from HPV, which form a virus like particle (VLP), 
and uses the adjuvant system AS04.  AS04 consists of alum as well as monophosphoryl lipid A 
(MPL)30.  MPL is an agonist of PRR toll like receptor 4 (TLR4), which also is triggered in 
response to the common bacterial PAMP lipopolysaccharide (LPS).  Unlike LPS, also known as 
endotoxin, MPL does not cause excessive inflammation and toxicity following injection.  The 
mechanisms that cause MPL to have reduced toxicity in comparison to wild type bis-
phosphorlyated lipid A remain an active area of research.  It is hypothesized that MPL more 
strongly triggers the Myd88 independent TRIF pathway of TLR4, resulting in type 1 interferon 
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production, whereas wild type LPS triggers both the Myd88 independent and the Myd88 
dependent proinflammatory pathway31.  In addition to Cervarix, MPL is being explored as an 
adjuvant for many different vaccines32–34. In November 2015, the FDA approved the first 
seasonal influenza vaccine to contain an adjuvant, Fluad—produced by Novartis35.  Fluad 
contains MF59, which is an oil in water emulsion of the biodegradable oil squalene36.  Though 
its approval in the U.S. is recent, vaccines adjuvanted with MF59 have been approved in Europe 
since 1997.  Similar to alum, it is not known why MF59 enhances the immune response, as it 
does not contain any specific PAMPSs.  However, it is suspected that its triggering of 
inflammasome complexes plays a role in eliciting the response37.  Also in 2015, the FDA 
approved the vaccine Bexerso for use in preventing meningitis B infection.  Bexsero contains 
recombinant proteins from Neisseria meningitidis, and is adjuvanted with alum as well as outer 
membrane vesicles derived from N. meningitidis38. Outer membrane vesicles retain the PAMPs 
of the bacteria they are derived from, but are non-infectious, making them safe to use without 
further inactivation.  The increase in FDA approved vaccines with diverse adjuvants highlights 
the impact that adjuvant choice can have on vaccine efficacy. 
 
Outer membrane vesicles: a new class of adjuvants 
The FDA approval of Bexsero marked the first time that a vaccine using outer membrane 
vesicles (OMVs) as an adjuvant was widely available. OMVs are classified as either ‘native’, 
where the OMVs are naturally shed off from bacterial membranes, or ‘nonnative’, where OMVs 
are synthetically created from bacterial membranes, commonly through sonication or detergent 
extraction39,40.  Bexsero contains ‘nonnative’ OMVs, formed by using detergent to extract them 
from N. meningitidis41.  Because nonnative OMVs are often formed by sonicating and shearing 
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bacteria, they contain proteins in their lumen from both the perisplasm and the cytoplasm of the 
bacteria from which they were derived39,40.  While nonnative OMV production allows for high 
batch-to-batch conformity, nonnative OMVs require more downstream processing to produce 
than native OMVs, which are simply collected from the supernatant in which the bacteria were 
cultured.  These ‘native’ OMVs, though more variable than nonnative OMVs, also hold potential 
as a vaccine adjuvant.   
 Currently, all gram-negative bacteria have been found to produce native OMVs.  OMVs 
are nanoscale vesicles (~50-200 nm) that shed off from the outer membrane of bacteria, without 
disrupting the outer membrane integrity. Numerous reviews have explored why and how bacteria 
produce these vesicles42–45.  OMV production has been found to be upregulated during periods of 
bacterial stress, such as when bacteria are exposed to increased temperatures, or when they are in 
the presence of antibiotics.  One theory behind OMV production is that it is a method for 
exporting misfolded proteins; misfolded proteins accumulate in the periplasm prior to being 
exported within OMVs46.  OMVs have also been shown to contribute to bacterial pathogenesis; 
OMVs can keep toxins concentrated over long distances, then penetrate other cells and deliver 
them.  OMV secretion is also associated with the formation of biofilms.  Finally, OMV secretion 
can be used as a method of bacterial quorum sensing.  Though native OMV production occurs 
naturally, gene knockout can be used to increase OMV production.  For example, knockout of 
the gene new lipoprotein 1 (nlpI) results in approximately 300x greater vesiculation rates47.  
While OMV production is useful to bacteria, it can also be exploited for use in vaccine 
production. 
 One approach to using OMVs in vaccine design is to simply collect native, or create 
nonnative, OMVs from the pathogen of interest, and then use them to supplement the vaccine 
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formulation.  OMVs offer the advantage of naturally containing many PAMPS, and because 
OMVs are unable to replicate, there is no need to inactivate them or to treat them with chemicals. 
However, it should be noted that nonnative OMVs are sometimes produced using detergents and 
are often treated to remove LPS48.   In addition to using N. meningitidis derived OMVs in a 
meningitis vaccine, E. coli derived OMVs have been explored as a method for generating a 
vaccine against sepsis and E. coli poisoning; Vibrio cholerae derived OMVs as a method for 
preventing cholera; and Bordetella pertussis OMVs as a method for preventing whooping 
cough49–51.  Though Bexsero combines OMVs with recombinant proteins, theoretically, use of 
pure OMVs as a vaccine could obviate the need for protein production and purification.  Instead, 
OMVs could just be collected and used without further components to immunize.  However, 
producing OMVs still does require growing up pathogens to collect/produce the OMVs from.  
Recently though, researchers have begun to engineer OMVs to display recombinant proteins so 
that working with the actual pathogens is not necessary52. 
 Recombinant outer membrane vesicles (rOMVs) use a transmembrane protein to display 
peptide and protein antigens on the surface of outer membrane vesicles53.  Currently, rOMVs are 
primarily produced using different strains of E. coli to express and display exogenous antigens, 
though other strains of gram-negative bacteria could likely be used as well.  E. coli strains that 
contain nlpI knockouts hypervesiculate, making them excellent candidates for production of 
native OMVs.  Transformation of these hypervesiculating strains with a plasmid encoding a 
transmembrane protein, cytolysin A (ClyA), followed by an antigen of interest, results in the 
ClyA-antigen becoming embedded in the outer membrane of E. coli and subsequently shed in 
vesicles (Figures 1A-C). 54.  ClyA is a 34 kDa pore forming cytotoxin that is typically only 
expressed in pathogenic E. coli strains grown in anaerobic conditions.  ClyA can be secreted in 
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OMVs, where it typically assembles into an 8 or 13 oligomeric pore complex, capable of causing 
hemolysis and cytotoxicity55.  While the exact mechanism for how ClyA is translocated to the 
outer membrane remains unknown, it has been proven that ClyA does not need to be cytolytic in 
order to translocate.  A cytotoxin-based vaccine platform might not seem like the safest vaccine 
option; however, Kim et al. demonstrated that genetically fusing an antigen to ClyA eliminated 
its cytotoxicity, perhaps by preventing oliogmerization into the pore complex from occurring52. 
Kim et al. also demonstrated that when ClyA was genetically fused to green fluorescent protein 
(GFP), rOMVs were produced that fluoresced, thus suggesting that ClyA could be used to 
display conformational epitopes on the outside of rOMVs as well as linear epitopes. The ease of 
DNA recombinant technology means that the plasmid containing ClyA can be quickly modified 
to insert different protein-based antigens for expression.   
rOMVs offer the advantage of not requiring additional adjuvants to create a vaccine; 
simply suspending ClyA-GFP rOMVs in PBS results in high anti-GFP titers in BALB/c mice 
(Figure 1D)54.  Unlike most subunit vaccine delivery systems, which require at a bare minimum 
two components to be mixed together (adjuvant and antigen), rOMVs couple antigen and 
adjuvant directly. Work in BALB/c mice comparing the immune response to ClyA-GFP rOMVs 
made in a common lab strain of E. coli, JC8031, to GFP adjuvanted with alum, showed that both 
elicited high levels of anti-GFP IgG antibodies that had approximately equivalent levels of IgG1 
and IgG2a.   When ClyA-GFP rOMVs were made from a probiotic strain of E. coli, E. coli 
Nissle 1917 (Nsl), a similar level of anti-GFP IgG antibodies was produced, but there were 
significantly more IgG2a antibodies than IgG1, indicating a useful Th1 bias57.  Further 
investigation revealed that a cellular response was also elicited when mice were vaccinated with 
ClyA-GFP Nsl rOMVs. The high titers generated by both JC8031 and Nsl derived rOMVs 
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indicated that they would make good vaccine adjuvants, with the Th1 biased nature of the 
immune response to Nsl rOMVs making them a particularly intriguing vaccine platform.  
However, though the titers and cellular results were promising, GFP is an irrelevant antigen in 
preventing infectious disease.  In order to determine whether rOMVs have potential as a vaccine 
platform, they need to be engineered to display a pathogen-derived antigen and tested in a 
challenge model.    
 
 
 
Figure 1:. Process of producing native rOMV vaccines. A.) E. coli are transformed with a 
plasmid encoding a transmembrane protein, ClyA, and an antigen of interest. B.) Transformed E. 
coli start to express ClyA-antigen protein, which translocates to the outer membrane of E. coli. 
The outer membrane of E. coli naturally buds off, forming rOMVs. C.) rOMVs are studded with 
ClyA-antigen. D). rOMVs are collected using a series of centrifugation steps, suspended in PBS, 
and used as a vaccine. 
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Influenza: a persisting global health challenge 
Annually, 5-10% of adults and 20-30% of children will be infected with seasonal influenza, 
leading to about 3-5 million severe cases and 250,000-500,000 deaths worldwide58.  Influenza 
pandemics can also occur, as happened in 1918, 1957, 1968, and 200959.  Though seasonal 
influenza vaccines exist, influenza’s high mutation rate often renders them ineffective.  
Additionally, seasonal influenza vaccines are ineffective against pandemic strains of influenza. 
Influenza is a negative sense RNA virus that is a member of the Orthomyxoviridae family and 
can be divided into 4 types: A, B, C, and D60.  While both influenza A and B are capable of 
producing severe disease in humans, only influenza A can cause pandemics.   
Influenza A virus (IAV) is an approximately spherical virus (~ 80 -120 nm in diameter) 
comprised of a bilipid membrane studded with 3 proteins: hemagglutinin (HA), neuraminidase 
(NA), and transmembrane matrix protein 2 (M2) (Figure 2).  The HA and NA proteins are used 
to divide IAV into different subtypes; currently, there are 18 different HA subtypes and 11 
different NA subtypes61.  Matrix 1 protein (M1) forms a layer underneath the lipid membrane to 
which IAV’s ribonucleoproteins (RNP) associate.  The RNP complexes are comprised of one of 
IAV’s 8 RNA segments bound to the polymerase (P) proteins PA, PB1, and PB2, as well as to 
nucleoprotein (NP). Small amounts (130- 200 copies) of nuclear export protein (NEP, also 
known as NS2) are also located within the virion’s core.  In addition to these 9 proteins, 
influenza encodes non-structural protein 1 (NS1), which helps limit host interferon (INF) 
production, as well as several other proteins (PB1-N40, PA-X, PA-N155, PA-N182, M42, NS3) 
whose roles are still being defined62.   
IAV initiates cellular infection by binding HA to sialic-acid (SA) containing receptors on 
cell surfaces63. Following binding of HA (which must be cleaved to be infectious), the influenza 
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virion is endocytosed through receptor mediated endocytosis.  The endosome decreases in pH as 
it progresses through the cell.  The decreased endosomal pH activates the M2 ion channel, which 
starts pumping H+ ions into the virion’s core, causing the RNPs to dissociate from M1. When the 
endosome pH reaches about 5, HA (cleaved) undergoes a conformational change, allowing a 
fusion peptide to insert into the endosome’s membrane.  This results in the endosomal and viral 
membrane fusing together and the freeing of the viral RNPs.  The RNPs travel to the nucleus 
where the vRNA is transcribed into positive sense mRNA for protein production and is also 
replicated to make more vRNA.  The HA, NA, and M2 proteins are produced in the rough 
endoplasmic reticulum and then exported to the cell membrane, where they are joined by the 
cytoplasmically produced nonstructural proteins and vRNA.  Complete viruses bud off with 
assistance from the NA protein, which cleaves SA from the cell’s surface64.   
 
 
Figure 2: Schematic of influenza virion. Influenza is 
categorized into subtypes based on the hemagglutinin 
and neuraminidase type.   
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Influenza is a difficult pathogen to target through vaccination, due largely to its high 
mutation rate and ability to form new strains when two different strains co-infect (antigenic drift 
and shift)65,66. Current influenza vaccines work by forming antibodies against prominent external 
influenza proteins (hemagglutinin and—to a lesser extent—neuraminidase), preventing cellular 
entry.  However, these antibodies are typically not cross strain protective and lose effectiveness 
as influenza evolves67. Thus, it is necessary to develop new influenza vaccines each year.  It 
takes about 6 months to develop a new vaccine, necessitating scientists to predict which strains 
will be most prevalent before the flu season begins, resulting in vaccines that vary greatly in 
effectiveness from year to year.  Live-attenuated, inactivated, and subunit influenza seasonal 
vaccines are typically available that are either trivalent (1 strain is influenza B) or quadrivalent (2 
strains are influenza B).  Some of the inactivated vaccines are mixed with an adjuvant to ensure a 
sufficient immune response. The live-attenuated influenza vaccine is cold-adapted, only 
replicating in the cooler nasal passages66.  While improved adjuvant systems could lead to 
stronger immune responses being generated by the seasonal flu vaccine, the larger problem is 
that the antigens being targeted in the seasonal flu vaccine are so variable; even if a seasonal flu 
vaccine elicits a strong antibody response, that response is useless if it is directed against an 
irrelevant HA type.   
The holy grail of influenza work is to create a ‘universal’ influenza A vaccine68–70.  This 
vaccine would offer protection to both seasonal and pandemic strains of influenza, and would not 
require annual updates.  Creating a single vaccine that protects against even unknown influenza 
strains requires directing the immune response against highly conserved influenza antigens.  One 
approach has been to generate neutralizing antibodies against the stem of HA, as this portion is 
more conserved than the head region71.  However, most of influenza’s highly conserved proteins 
 	  
	  
13 
are located internally, making neutralizing antibodies ineffective.  Instead, the vaccine would 
need to elicit CD8+ T cells to kill the entire influenza infected cell.  In humans, influenza 
specific T cells from one IAV subtype infection help to prevent influenza infection from a 
different IAV subtype infection72.  However, anti-HA antibodies from one IAV subtype infection 
do not typically prevent influenza infection from a different IAV subtype infection.  Current 
influenza vaccines do a poor job at generating cross-reactive T cells, thus, there is need for 
development of a vaccine that could elicit a T cell response, contributing to clearance of infected 
cells73,74.   
In addition to CD8+ T cells killing infected cells, ADCC and AMP can also lead to cell 
death75.  In this case, the variable region (Fab) of IgG antibodies binds to antigens on the infected 
cell surfaces and the crystalline region (Fc) binds to Fc receptors on immune cells, such as NK 
cells and macrophages, triggering cell death via cytokine secretion or phagocytosis.  Proteins that 
are typically hidden on pathogens are sometimes exposed after the pathogen has infected a cell 
and begun to produce copies of itself.  One such protein is the matrix 2 (M2) protein of IAV. 
The tetrameric M2 protein of IAV is encoded on influenza’s vRNA segment 7 and consists 
of an N-terminal ectodomain, transmembrane domain, and intracellular C domain76. The N-
terminal ectodomain (amino acids 2-24) of M2 (M2e) is one of the most conserved regions in 
human influenza; between 1918 and 2008, nearly all circulating human influenza strains had the 
same sequence77. In 2009, the swine-origin influenza virus contained an avian vRNA 7 segment 
that encoded 4 amino acid changes in the M2e region, indicating that the region was not 
completely conserved78.  Despite these differences, the M2 ectodomain has significantly less 
variation than HA.  This lack of variation is likely due to M2e experiencing less evolutionary 
pressure (very few antibodies are generated against M2e during infection) and to M2e and M1 
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both being encoded on the same vRNA (M2 is formed from a spliced version of M1’s mRNA).  
Though M2e is exposed on IAV’s surface, it is highly inaccessible to neutralizing antibodies due 
to the overhanging HA and NA glycoproteins.  However, when influenza infects a cell and starts 
exporting proteins, HA and NA cluster together in lipid rafts on the cell surface, whereas M2 is 
more dispersed, making it possible for antibodies to bind79.  The high level of M2e conservation, 
as well as its exposure on infected cells, suggests it would make an excellent universal influenza 
vaccine target77. 
 The concept to target influenza through M2e has been around for over a decade80.  In 
1999, Neirynck et al. demonstrated heterologous protection against mouse adapted influenza 
strains X47 (H3N2) and PR8 (H1N1) when vaccinating with M2e fused to a hepatitis B virus 
core protein (along with adjuvants).  Since then, numerous animal studies involving M2e have 
been published, many of which were recently reviewed by Deng et al77. M2e has been delivered 
numerous ways using many different constructs.  M2e conjugates have been formed using 
flagella, keyhole limpet protein (KHL), and Neisseria meningitidis outer membrane protein 
complex81–84.  Additionally, influenza A DNA vaccines have been made that express M2e as 
well as whole M2.  M2e-based vaccines have also been included in several clinical trials.  The 
company Dynavax tested an influenza vaccine comprised of a proprietary TLR9 ligand fused to 
M2e and NP and found it resulted in strong anti-M2e titers with only mild side effects during a 
Phase I clinical trial initiated in 2010.  However, Dynavax has not published any papers on the 
vaccine, nor made any press releases about it since then, suggesting that the project may be on 
hold.  Another Phase I clinical trial involving an M2e-based vaccine (ACAM-FLU-ATM), 
initially showed promising results, with anti-M2e seroconversion rates of 90%, but titers quickly 
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dropped after 45 days, resulting in Phase II clinical trials not being pursued77.  Thus, while M2e 
vaccines show promise, there are still many aspects to be improved.   
 Possibly, an improved adjuvant system would allow for increased success of M2e-
vaccines.  The strong adjuvancy of rOMVs, and Th1 biased response of Nsl rOMVs, suggests 
that they would be a good platform for use in developing an M2e-based vaccine.  Additionally, 
rOMVs naturally contain many of the TLR agonists that other M2e-based vaccines had to add 
separately, making rOMVs a simpler platform85. Finally, modifying the strains of E. coli used to 
produce the rOMVs to have less stimulatory LPS would both eliminate the need to do any post-
processing of the rOMVs to remove endotoxin and minimize possible side effects following 
vaccination. During this dissertation, I will explore ways to use rOMVs to generate M2e-based 
influenza vaccines with heterosubtypic and long-lasting protection.   
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CHAPTER 2 
RECOMBINANT M2E OUTER MEMBRANE VESICLE VACCINES PROTECT AGAINST 
INFLUENZA A CHALLENGE IN BALB/C MICE 
Introduction 
Influenza remains a significant source of morbidity and mortality throughout the world, despite 
the availability of seasonal vaccines. Each year, 5-10% of adults and 20-30% of children are 
infected with seasonal influenza, leading to 3-5 million severe cases and 250,000-500,000 deaths 
worldwide 1.  Additionally, influenza A viruses have the potential to form pandemic strains via 
cross-species reassortment, as evidenced by the 1918 (Spanish flu), 1957 (Asian flu), 1968 
(Hong Kong flu), and 2009 (swine-origin flu) pandemics, presenting a threat to global health 2.  
Current influenza vaccines primarily target the immune response against the immunodominant—
but hyper variable—glycoproteins hemagglutinin (HA), and to a lesser extent, neuraminidase 
(NA), necessitating annual development of strain-specific vaccines 3. Accordingly, there is great 
public and scientific interest in the creation of a universal influenza A vaccine to obviate or 
reduce the need for yearly vaccination and to protect against pandemic strains 4,5.   
One promising target antigen for a universal vaccine is M2e, the ectodomain of the 
influenza A matrix protein 2 (M2), a homotetrameric ion channel with roles in viral entry and 
budding, first explored as a vaccine target by Richardson et al. in 1985 6. M2e demonstrates 
remarkable conservation of its 23 amino acid sequence, especially among influenza A viruses of 
the same host restriction. This high conservation has been attributed to M2e’s genetic 
relationship with M1–an integral structural protein–and the lack of selective pressure against 
M2e due to M2e’s low virion presence and immunogenicity 7.  Although steric hindrance from 
HA and NA limits antibody recognition of M2e upon the virion surface, exposed M2e is 
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abundantly displayed on the membranes of infected epithelial cells 8.  Therefore, while anti-M2e 
antibodies are unable to neutralize the virus directly, they facilitate clearance of infected cells via 
antibody dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP) 9,10. 
 During influenza infection, ADCC and ADCP are performed by alveolar macrophages 
and natural killer (NK) cells that recognize the Fc regions of antigen-bound antibodies and 
display selective efficacy with respect to antibody isotype 11. It has been previously shown that 
IgG2a isotype antibody levels, associated with a Th1 type immune response in mice, correlate 
significantly with enhanced survival against influenza challenge for M2e-based vaccines 10,12. 
Therefore, M2e-based vaccines have aimed to generate Th1-biased responses in an effort to 
improve protective efficacy. However, many methods that generate a Th1 bias require 
supplementation with viral components or cost-prohibitive adjuvants 13–16. Here, we utilize a 
recently developed adjuvant system, recombinant outer membrane vesicles (OMVs), to elicit 
preferential production of IgG2a antibodies against M2e without addition of viral components or 
soluble adjuvant. 
OMVs are nanoparticles naturally produced by gram-negative bacteria with complex 
adjuvant profiles that are parent strain dependent and can promote a robust Th1-biased response 
when designed accordingly 17,18.  Furthermore, OMVs can be engineered to display recombinant 
heterologous proteins by transforming hypervesiculating (ΔnlpI) strains of E. coli with a plasmid 
encoding the transmembrane protein ClyA followed by the antigen of interest 19,20. Previously, 
we have shown that OMVs derived from the probiotic E. coli strain Nissle 1917 (EcN) carrying a 
model antigen, green fluorescent protein (GFP), promoted a Th1-biased response directed 
against GFP 18. Here, we demonstrate that the display of M2e-based peptides on the surface of 
OMVs derived from EcN generate high levels of IgG2a antibodies—indicative of a Th1 bias—
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and protect against a lethal challenge with influenza A virus.  To ascertain the influence of the 
innate immune system on the observed response, the agonist activity of OMVs on toll like 
receptors (TLR) was quantified to help understand the mechanisms through which the OMVs 
function as an adjuvant. 
 
	    
 	  
	  
26 
Methods 
Plasmid and expression vector design 
M2e-based genetic sequences were cloned into a pBAD 18-CM plasmid containing 
transmembrane protein ClyA, as previously described 19.  Briefly, three M2e-based genetic 
sequences with a terminal histidine-tag were designed and codon optimized for E. coli (GeneArt 
service, LifeTechnologies, Waltham, U.S.) (Figure 1BC, SI). Gene blocks were inserted into a 
pBAD18-CM vector directly 3’ terminal to the ClyA-encoding region.   
 
OMV production and characterization 
OMVs were prepared as previously described 18,20.  Briefly, E. coli Nissle 1917 ΔnlpI (EcN) 
cultures transformed with appropriate plasmid were grown overnight, subcultured to OD600 = 
0.08 in Miller LB broth (ThermoFisher Scientific, Waltham, U.S.), grown to mid-log phase, then 
induced with 0.2% L-arabinose (Sigma-Aldrich, St. Louis, U.S.) (Figure 1A). Cultures were 
grown at 37˚C for 18 hours, centrifuged (5000x g, 4 °C, 15 min) to pellet bacteria, then sterile 
filtered (0.2 µM). OMVs were isolated from the filtrate by ultracentrifugation (26k rpm, 4 °C, 
3h) and suspended in PBS. Total protein concentration was determined by Pierce BCA Protein 
Assay (ThermoFisher Scientific, Waltham, U.S.) and antigenic content was measured by 
Western Blot with anti-His6x primary antibody (Sigma-Aldrich, St. Louis, U.S.).  Previous work 
provides detailed analyses of the proteins and sugars present within EcN OMVs [18]. 
 
Immunization 
Female BALB/c mice (Jackson Laboratories, Bar Harbor, U.S.) were immunized subcutaneously 
with 100 µL of vaccine at age 8-weeks. Treatment groups M2e1xC-OMV (n=5), M2e1xS-OMV 
 	  
	  
27 
(n=12), and M2e4xHet-OMV (n=12) received 40 µg total protein of OMVs containing ~0.2 µg 
total M2e antigen in PBS. Group M2e1xS with alum (n=12) received 1 µg M2e1xS peptide 
(NH2-SLLTEVETPIRNGSRSNDSSD-COOH, Lifetein, Somerset, U.S.) in PBS adsorbed to 2% 
Alhydrogel® (Invivogen, San Diego, U.S.) at a 1:1 [v/v] ratio. A sham vaccination group 
received only PBS (n=12).  Prime and boost doses were administered 4 weeks apart.  Blood was 
collected 1-2 days before the prime dose and every 2 weeks following. For passive transfer 
experiments, five 8-week old female BALB/c mice were immunized intraperitoneally (ip) with 
100 µL pooled serum diluted to 500 µL in PBS collected 2 weeks prior to challenge from 
M2e4xHet-OMV (n=5), PR8 pre-exposed (n=5), or sham PBS (n=5) vaccinated mice.  Blood 
was collected 24h post ip injection and analyzed via ELISA to ensure successful antibody 
transfer. All mouse work was conducted according to protocols approved by Cornell’s 
Institutional Animal Care and Use Committee (IACUC). 
 
Influenza challenge 
A/Puerto Rico/8/1934 (PR8) virus (BEI Resources, Manassas, U.S) was diluted in PBS and 
administered via intranasal injection of 50 µL PBS under isofluorane anesthesia.  Mice 
immunized via PR8 exposure (pre-exposed mice) were administered a sub lethal dose of 5 
fluorescence forming units (FFU) PR8 virus at age 8 weeks.  M2e1xC-OMV (n=5), M2e1xS-
OMV (n=4), M2e4xHet-OMV (n=8), M2e1xS with alum (n=4), sham (PBS) vaccination (n=9), 
and pre-exposed (n=13) cohorts received a lethal dose (50 FFU) 10 weeks post initial exposure 
or vaccination. For passive transfer experiments, 8-wk old mice received 50 FFU PR8 24h post 
passive transfer.  Weight loss greater than 30% or signs of severe distress were used as 
euthanasia criteria. 
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Viral load quantification via Fluorescence Forming Unit (FFU) assay 
Day 6 following PR8 challenge, mice were sacrificed from sham, M2e4xHet-OMV, and pre-
exposed groups (n=3/group) and their lungs and trachea isolated and homogenized.  
Homogenates were centrifuged at 5000x g for 10 minutes at 4˚C, filtered (0.2 µm), and stored at 
-80˚C. For FFU assay, sample aliquots were diluted into MEM media containing 0.2% BSA and 
activated with TPCK Trypsin at 37˚C (1 µg/ml) for 20 minutes then deactivated with soybean 
trypsin inhibitor (8.4 µg/ml) (Corning, Tewksbury, U.S.). Samples were serially diluted, 100 µL 
loaded into 96-well plates with confluent layers of MDCK cells, and incubated for 24 hours. 
Cells were stained with mouse anti-nucleoprotein from hybridoma H16-L10-495 (ATCC, 
Manassas, U.S.) and Hoechst (ThermoFisher Scientific, Waltham, U.S.) then imaged as 
described previously 21. FFU/mL was back-calculated from the number of infected cells at the 
lowest infected dilution.  
 
Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were conducted on serum samples as previously described, with the modification that 
plates were coated with 2 µg/mL M2e1xC peptide in PBS at 37 °C overnight 18. Antibody titer 
was defined as the reciprocal of the greatest dilution at which the OD450 of vaccinated serum 
exceeded the OD450 of pre-vaccinated serum plus 3 standard deviations. The lowest titer 
detectable by ELISA was 1:500, owing to high background at higher concentrations. 
 
Toll-like receptor (TLR) ligand activity assay 
TLR panel using HEK-Blue KD-TLR 5 cells (Invivogen, San Diego, U.S.) was conducted as 
described for HEK293 cells 18.  Briefly, 1.5x105 cells/well were seeded in 96-well plates and 
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transfected using TransIT-LT1 (Mirus, Madison, U.S.) with plasmids encoding human or mouse 
TLRs (TLR2, TLR3, TLR4 and MD2, TLR5, TLR7, TLR8, TLR9, mTLR2, mTLR3, mTLR4 
and mMD2, mTLR9, mTLR11), CMV-β-galactosidase and 5xNF-κB-luciferase. After 24 h, 
cells were stimulated with 4xM2eHet-OMVs (10 ng/mL), positive control (TLR1/2: Pam3Cys, 1 
µg/mL; TLR3: poly(I:C), 1 µg/mL; TLR4: LPS, 100 ng/mL; TLR5 and TLR11: flagellin from S. 
typhimurium, 100 ng/mL; TLR7: loxoribine, 100 µM, TLR9: CpG 10104, 3 µM (Invivogen, San 
Dieogo, U.S.) or PBS for 18h.  Media was then removed, reporter lysis buffer, 100 µL/well, 
(Promega, Madison, U.S.) added, and cells mechanically lysed.  Lysate (20 µL/well) was added 
to opaque 96-well plates and relative light units (RLUs) quantified using a Veritas luminometer 
(Promega, Madison, U.S.) through addition of 100 µL D-luciferin substrate per well. 4xM2eHet-
OMV TLR5 stimulation was further confirmed using the same method with HEK293 cells 
(Figure S1). 
 
Statistics 
Antibody titers are reported as geomean titers (GMT) with error bars representing 95% 
confidence intervals.  Comparisons between IgG1 and IgG2a titers use a paired 2-tailed t-test on 
log-transformed samples. Luciferase levels of PBS vs. M2e4xHet-stimulated cells in TLR panel 
are compared using a two-tailed t-test. Kaplan-Meier survival curves analyzed using log-rank 
test with Bonferroni-corrected alpha to account for multiple comparisons. Anti-M2e titer vs. 
percent weight loss was analyzed using a linear regression model in which the natural log of the 
titer was plotted against the maximum percent weight loss each mouse experienced during the 
challenge.  All statistical analyses were conducted using Prism6 software (GraphPad software, 
La Jolla, U.S.).   
 	  
	  
30 
Results 
Production of OMVs containing M2e derived peptides 
Three M2e-based OMV vaccines were designed and produced to determine the effect of antigen 
choice upon immunogenicity and protective efficacy (Figure 1BC). Here, we designed OMVs 
that display the most common human-type influenza A virus M2e antigen (M2e1xC-OMVs) as 
well as its serine analog (M2e1xS-OMVs). The native cysteines of M2e (C17 and C19) are 
frequently substituted with serines to prevent disulfide bond formation and aggregation, which 
may inhibit function or expression, though we did not encounter any difficulties in expression 22. 
Additionally, while M2e is highly conserved amongst influenza A strains that infect a common 
host, M2e is divergent across host restrictions 23. Recently, the Kang group showed improved 
immune recognition of broadly divergent influenza A strains by vaccination with a 5xM2e 
tandem construct containing heterologous host-restricted epitopes 24,25. Therefore, a 4x 
multimeric construct (M2e4xHet-OMVs) consisting of the serine analogs of human, swine, and 
two avian influenza A restricted M2e variants—connected by flexible (G3SG3) linkers to provide 
epitope separation—was produced (Figure 1BC). Successful expression and localization of 
ClyA-M2e fusion proteins in OMVs was confirmed via Western blot of isolated vesicles (Figure 
1D). TEM images of EcN-derived M2e-OMVs showed they were in the expected size range of 
50-100 nm in diameter and consistent with native OMVs (Figure 1E).   
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Figure 1: A: Hypervesiculating E. coli strain Nissle 1917 ΔnlpI was transformed with a pBAD 
plasmid that encodes transmembrane protein ClyA followed by an M2e-based antigen, resulting 
in production of outer membrane vesicles (OMVs) that display the desired antigen.  B. Three 
ClyA-M2e constructs terminated by a 6x histidine-tag were expressed in E. coli: M2e1xC, 
M2e1xS, and M2e4xHet.  M2e1xC contains a common human restriction M2e variant, M2e1xS 
contains the serine analog to M2e1xC, and M2e4xHet contains the serine analog to M2e1xC, 
along with the serine analogs to a common swine restricted M2e variant and two avian restricted 
variants.  C. M2e contains several variants, largely dependent on host restriction. The sequence 
of M2e in the virus used for challenged, A/Puerto Rico/8/1934 (PR8), along with the sequences 
of M2e used to create M2e-based constructs (Human (C), Human (S), Swine, Avian (1), and 
Avian (2)) are listed.  D. Western blot of M2e-OMV constructs demonstrates that M2e1xC, 
M2e1xS, and M2e4xHet are present in OMVs (5 µg total protein/well, anti-His antibody).  E. 
Transmission electron microscopy (TEM) images of OMVs show polydispersed particles 
ranging approximately 50-100 nm in diameter (uranyl acetate staining).  
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M2e-OMV vaccination leads to high IgG titers 
M2e1xC-OMV, M2e1xS-OMV, and M2e4xHet-OMV vaccinated mice all developed high and 
statistically equivalent anti-M2e IgG titers 8 weeks post initial vaccination that were all 
significantly higher than those of the M2e1xS alum cohort (**** p<0.0001) (Figure 2A). Mice 
that were pre-exposed to a low dose of PR8 also developed high titers that were significantly 
higher than the M2e1xS alum cohort (** p<0.01). Despite a 5x mole excess in M2e content 
compared to M2e1xS-OMVs, the M2e1xS peptide adsorbed to alum was unable to generate a 
robust immune response.  
 Serum from vaccinated mice was further assessed to compare the IgG2a:IgG1 ratio.  
IgG2a isotype antibodies, associated with a Th1 type immune response, are the proposed 
correlate of protection for M2e-based vaccines and are necessary and sufficient for protection 
10,12. All three M2e-OMV groups showed a significant elevation in IgG2a titers over IgG1 titers 
(* p<0.05) (Figure 2B), as did the cohort pre-exposed to PR8 (** p<0.01). This elevated 
IgG2a:IgG1 ratio is of particular significance as it occurred in BALB/c mice, which are naturally 
biased toward a Th2 response with higher IgG1 levels than IgG2a 26.  Additionally, no 
supplementation with additional extrinsic adjuvants, such as MPL or RNA and viral components, 
was required to generate this isotype distribution 27–29.  
 	  
	  
33 
	  
Figure 2: Mouse serum was analyzed for anti-M2e titers 8 weeks post initial vaccination. 
Dotted line represents lowest titer detectable above background.  A. All three M2e-OMV 
vaccines yielded an IgG titer higher than that of M2e1xS peptide with alum 
(****p<0.0001).  IgG titers from M2e1xC-OMVs, M2e1xS-OMVs, and M2e4xHet-OMVs 
did not have any statistical difference (p>0.05). Additionally, pre-exposed mice developed 
titers that were significantly higher than M2e1xS + alum (**p<0.01). Log transformed titers 
were analyzed using a one-way ANOVA followed by multiple comparisons that were 
corrected by Tukey’s test. B. All M2e-OMV vaccines resulted in statistically elevated titers 
of IgG2a relative to IgG1, indicating a Th1 bias (*p<0.05).  As expected the Th1 bias from 
mice pre-exposed to PR8 was especially robust (**p<0.01). The serum from mice 
vaccinated with M2e1xS with alum could not be analyzed for IgG1 vs. IgG2a titers as it 
was beneath the range of the ELISA assay.  Log transformed IgG1 and IgG2a titers were 
compared in paired, 2-tailed t-tests. All graphs display geomean titers (GMT) with error 
bars that represent 95% confidence intervals.  Data analyzed using Prism6 software.    
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M2e-OMV vaccines protect BALB/c mice from influenza A challenge 
M2e4xHet-OMVs provided the best protection against PR8 with 100% survival post challenge 
(Figure 3AB). Additionally, the average lung and trachea viral titer of M2e4xHet-OMV 
vaccinated mice was approximately 10-fold lower than that of the sham (PBS) control at day 6 
post challenge (Figure 3C).  All sham (PBS) control mice succumbed to infection by day 10 
post-challenge, confirming a lethal challenge dose.  As titer data predicted, M2e1xS with alum 
mice fared poorly, with only 25% survival (1/4).  Responses to vaccination with M2e1xC-OMVs 
and M2e1xS-OMVs were comparable, with 40% (2/5) survival and 50% survival (2/4) 
respectively. Survival analysis demonstrated that only M2e4xHet-OMVs provided better 
protection than that of the sham (PBS) vaccine (p<0.01) (Figure 3B). 
M2e4xHet-OMV vaccinated mice showed the least morbidity of the vaccinated groups, 
with an average body weight loss of 14% (Figure 3A).  Though the M2e4xHet mice showed 
greater weight loss than the pre-exposed mice, this result is expected, as M2e-based vaccines are 
infective permissive, requiring Fc-dependent clearance of infected cells by the innate immune 
system for protection 10. Linear regression analysis of log transformed anti-M2e total IgG titers 
vs. the lowest percent original weight yielded a significant relationship (r2=0.403, p<0.05) 
(Figure 3D).  The literature suggests IgG2a is a correlate of protection for M2e; therefore, we 
next analyzed IgG2a vs. lowest percent original weight and found an even stronger relationship 
(r2= 0.477, p<0.01) (Figure 3F), whereas IgG1 titers vs. lowest percent original weight did not 
have a significant relationship (r2=0.228, p>0.05) (Figure 3E) 10,12,30.  
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Figure 3: Mice were challenged with a lethal dose (50 FFU) of mouse adapted influenza A virus 
PR8 10 weeks after prime vaccine dose. Mortality (A) and morbidity (B) graphs show that 
different vaccines resulted in different levels of protection. As expected, all pre-exposed mice 
survived challenge and all sham vaccinated (PBS) mice died/required euthanasia. Mice that 
received the M2e4xHet-OMV vaccine fared best, with the highest survival rate (100%) and the 
least weight loss (apart from pre-exposed).  Mice vaccinated with M2e1xS with alum fared 
worst, 25% survival, and M2e1xS-OMV and M2e1xC-OMV vaccinated mice fared 
intermediately, 50% and 40% survival respectively.  Error bars represent standard error of the 
mean. C. PR8 viral titer from lungs and tracheas excised on day 6 of challenge for M2e4xHet-
OMV, exposure-immunized, and sham PBS injection. D-E. Linear regression of anti-M2e IgG 
(D) IgG1 (E) and IgG2a (F) log transformed titers vs. minimum percent original weight of 
OMV-immunized mice during PR8 challenge.  The highest significance was found for IgG2a, 
followed by that for IgG.  IgG1 did not correlate significantly with weight loss.    
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M2e-OMVs stimulate multiple toll like receptors (TLRs)   
Following the success of M2e4xHet-OMVs in PR8 challenge, their impact on TLR signaling was 
explored.  TLR stimulation is important to drive an appropriate innate immune response against 
an antigen 31. HEK293 TLR5 KD cells were transfected with human and murine TLRs and 
stimulated with M2e4xHet-OMVs.  Comparable TLR stimulation patterns were found for both 
mouse and human TLRs, suggesting these OMVs would have similar adjuvant potency in 
humans and mice.  The most predominantly activated TLRs were TLR1/2, mTLR1/2, TLR4, 
mTLR4, and TLR5 (Figure 4) (* p<0.0001). TLR9 and mTLR9 were activated to a lesser extent 
(# p<0.01), suggesting a possible contribution to the innate immune response through these 
receptors. DNA is commonly found in OMVs, making it likely that the TLR9 stimulation was 
due to low levels of CpG DNA 32.  
 
 
	  
Figure 4: The toll like receptor (TLR) response to M2e4xHet-OMVs was analyzed 
using both human (A) and murine (B) TLRs. OMVs primarily stimulated TLR1/2, 
TLR4, TLR5, mTLR1/2 and mTLR4 (*p<0.0001), and to a lesser extent, TLR9 and 
mTLR9 (#p<0.01). Media vs. M2e4xHet-OMV stimulated luciferase production was 
compared using a 2-tailed t-test.  Error bars represent standard deviation of the mean.  
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Passive transfer of serum protects against influenza A challenge 
Consistent with previous reports of M2e mechanism of protection, passive transfer of serum 
from M2e4xHet-OMV vaccinated mice provided complete protection (100% survival) against 
subsequent lethal PR8 challenge (Figure 5A) 10,16,33,34. However, greater weight loss—25% 
versus 14%—occurred in the passive transfer vaccinated mice vs. M2e4xHet-OMV vaccinated 
mice. This may be due to the reduced concentration of antibodies in passively immunized mice, 
which had an anti-M2e IgG GMT titer of 24,000, as opposed to 102,000 in M2e4xHet vaccinated 
mice, which is consistent with the anti-M2e IgG titer vs. percent weight loss correlation (Figure 
3D).   
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Figure 5: Mortality (A) and morbidity (B) of mice immunized through passive transfer of 100 
µL of serum (Ab) from PR8 pre-exposed, M2e4xHet-OMV vaccinated, or sham vaccinated 
(PBS) mice 8 weeks following initial vaccination or exposure.  Mice were vaccinated with serum 
24h prior to challenge with 50 FFU of PR8.  Cohorts that received serum from the pre-exposed 
or M2e4xHet-OMV vaccinated mice had 100% survival during challenge.  All mice that 
received PBS serum died during challenge.  Though all mice passively immunized with serum 
from donor M2e4xHet-OMV vaccinated mice survived, they showed higher levels of morbidity 
than the M2e4xHet-OMV vaccinated donor mice in equivalent PR8 challenge.   
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Discussion 
The ectodomain of influenza A matrix protein 2 (M2e) is a popular target antigen for potential 
universal influenza A vaccines due to its remarkable conservation over time 35. To overcome its 
low immunogenicity, M2e requires a potent adjuvant, and as we and others have demonstrated, 
peptide-adsorbed alum alone inadequately primes the immune response against influenza 27,36.  
Subsequently, a range of subunit fusion vaccines that combine M2e with adjuvanting proteins, 
such as hepatitis B protein, keyhole limpet protein, and flagellin have been explored and 
developed, though many require supplementation by additional extrinsic adjuvants, such as 
incomplete Freund’s adjuvant or MPL 16,37,38.  Here, we demonstrated that engineering EcN to 
display M2e peptides upon OMVs resulted in significantly elevated anti-M2e IgG2a titers vs. 
IgG1 titers and protection against influenza challenge without supplemental adjuvants. 
Additionally, the IgG2a:IgG1 ratio of 3:1 is comparable to that of M2e vaccines supplemented 
with viral components 25. Future work will evaluate the ability of M2e-OMVs to give 
heterologous protection against multiple strains of influenza A virus, and thus better determine 
its potential as a universal influenza A vaccine.  
The proposed mechanism of protection for M2e-based vaccines is clearance of infected 
cells through antibody dependent cell cytotoxicity and phagocytosis (ADCC and ADCP) and it 
has been shown that IgG2a antibodies are both necessary and sufficient to provide protection in 
mice 10,16,33,34. Our results add further support to this proposed mechanism as we found that 
protection from weight loss during challenge most significantly correlated with IgG2a antibody 
levels. Furthermore, our minimum IgG2a antibody titer among passively immunized mice was 
8,000, adding strength to the reported minimum protective IgG2a antibody titer of 10,000 
previously suggested by Fiers et al. 30.  While only significant to p<0.1, M2e4xHet-OMV IgG2a 
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titers were higher than those of M2exC-OMV and M2eS-OMVs, perhaps contributing to the 
success of the M2e4xHet-OMV vaccine.  
 To further elucidate the potent adjuvant mechanisms of M2e-OMVs, we investigated the 
stimulation of the toll like receptor (TLR) family, as OMVs naturally contain a complex array of 
pathogen associated molecular patterns (PAMPS) 39. The TLR panel indicated that M2e4xHet-
OMVs trigger multiple bacteria-associated TLRs, predominantly TLR1/2, TLR4, and TLR5, 
and, to a lesser extent, TLR9. These TLRs signal through both the MyD88 (TLR1/2, TLR4, 
TLR5, TLR9) and TRIF/TRAF (TLR4) pathways, leading to NF-kβ activity and type I interferon 
production, which strongly promote a Th1 bias 40. Previous work characterized the response of 
murine TLRs to EcN OMV stimulation, but the work was conducted in HEK293 cells that 
endogenously express TLR5 18.  Here, we use HEK293 TLR5 KD cells to provide an enhanced 
perspective of OMV stimulation and to confirm that M2e4xHet-OMVs stimulate mouse and 
human TLRs similarly, suggesting translational possibilities.  One current limitation of this 
platform is that while the bacterial components of OMVs elicit potent immune responses through 
high levels of TLR stimulation, these components also limit the maximum tolerable dose which 
may be administered. Lipopolysaccharide (LPS), a molecule present in bacterial outer 
membranes, is a strong TLR4 agonist, but also a causative agent of sepsis.  M2e-OMV dose size 
was kept consistent with previous work involving OMV-based vaccines in which OMV LPS 
levels were measured and safe OMV dose sizes established [18,20]. However, further work in 
attenuating the LPS load in OMVs is ongoing and will permit larger does to be administered.  
Additionally, future work will explore other innate immune pathways, such as nucleotide-
binding oligomerization domain containing protein 1 (NOD1) signaling, to develop a more 
nuanced perspective on the signaling mechanisms of OMVs 31.  
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  In summary, M2e antigens presented on E. coli Nissle 1917 OMVs demonstrate 
protection against influenza A strain PR8.  The three OMV vaccines tested, M2e1xC, M2e1xS, 
and M2e4xHet, all yielded high anti-M2e IgG titers with significantly elevated IgG2a:IgG1 
ratios, and had improved survival over the peptide M2e1xS with alum formulation.  The 
heterologous M2e4xHet vaccine was most protective, resulting in 100% survival following 
challenge. TLR studies demonstrated that the OMV adjuvancy could be partly attributed to the 
OMVs triggering TLR2, TLR4, TLR5, which was consistent for both human and mouse TLRs.  
Naïve mice that passively received antibodies from M2e4xHet-OMV vaccinated mice showed 
100% survival following challenge. Overall, the data support the premise that OMVs represent a 
promising adjuvant platform for development of an M2e-based universal influenza vaccine.   
 
  
 	  
	  
42 
Acknowledgements	  
This work published in Vaccine, 4 March 2016. Co-authors are C. Garrett Rappazzo, Cassandra 
M. Guarino, Annie Chau, Jody L. Lopez, Matthew P. DeLisa, Cynthia A. Leifer, Gary D. 
Whittaker, and David Putnam.   
Research reported in this chapter was supported in part by the National Institute of Allergy and 
Infectious Diseases of the National Institutes of Health under Award Number 1R56AI114793-01.  
The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.  This work made use of the Cornell Center for 
Materials Research Facilities supported by the National Science Foundation under Award 
Number DMR-1120296. This material is based upon work supported by the National Science 
Foundation Graduate Research Fellowship to H.C.W. We thank Michele Bialecki and Kelly 
Sams (Cornell College of Veterinary Medicine) for their guidance and assistance in virological 
preparations, procedures, and assays; David Topham and Mark Sangster (University of 
Rochester School of Medicine and Dentistry) for productive discussion of results and 
experimental suggestions; and the members of the Putnam and Whittaker groups for 
encouragement and comments.  
 	  
	  
43 
References 
1.	   World Health Organization (2014). Seasonal Influenza Fact Sheet 
<http://www.who.int/mediacentre/factsheets/fs211/en/>.	  
2. Centers for Disease Control and Prevention (U.S.) (2014). CDC Resources for Pandemic 
Fluat <http://www.cdc.gov/flu/pandemic-resources/index.htm>. 
3. Treanor, JJ (2015). Prospects for broadly protective influenza vaccines. Vaccine: 1–
7doi:10.1016/j.vaccine.2015.08.053. 
4. Schotsaert, M and García-Sastre, A (2014). Influenza vaccines: a moving interdisciplinary 
field. Viruses 6: 3809–3826. 
5. Krammer, F and Palese, P (2015). Advances in the development of influenza virus 
vaccines. Nat. Rev. Drug Discov. 14: 167–182. 
6. Lamb, RA, Zebedee, SL and Richardson, CD (1985). Influenza virus M2 protein is an 
integral membrane protein expressed on the infected-cell surface. Cell 40: 627–633. 
7. Lamb, RA and Choppin, PW (1981). Identification of a second protein (M2) encoded by 
RNA segment 7 of influenza virus. Virology 112: 729–737. 
8. Leser, GP and Lamb, RA (2005). Influenza virus assembly and budding in raft-derived 
microdomains: A quantitative analysis of the surface distribution of HA, NA and M2 
proteins. Virology 342: 215–227. 
9. Jegerlehner, A, Schmitz, N, Storni, T and Bachmann, MF (2004). Influenza A vaccine 
based on the extracellular domain of M2: weak protection mediated via antibody-
dependent NK cell activity. J. Immunol. 172: 5598–5605. 
10. El Bakkouri, K, Descamps, F, De Filette, M, Smet, A, Festjens, E, Birkett, A, et al. 
(2011). Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc 
receptors and alveolar macrophages mediate protection. J. Immunol. 186: 1022–1031. 
11. Guilliams, M, Bruhns, P, Saeys, Y, Hammad, H and Lambrecht, BN (2014). The function 
of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14: 94–108. 
12. Schmitz, N, Beerli, RR, Bauer, M, Jegerlehner, A, Dietmeier, K, Maudrich, M, et al. 
(2012). Universal vaccine against influenza virus: Linking TLR signaling to anti-viral 
protection. Eur. J. Immunol. 42: 863–869. 
13. De Filette, M, Ramne, A, Birkett, A, Lycke, N, Löwenadler, B, Min Jou, W, et al. (2006). 
The universal influenza vaccine M2e-HBc administered intranasally in combination with 
the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544–551. 
14. Schotsaert, M, Ysenbaert, T, Neyt, K, Ibañez, LI, Bogaert, P, Schepens, B, et al. (2012). 
Natural and long-lasting cellular immune responses against influenza in the M2e-immune 
host. Mucosal Immunol. 6: 276–87. 
 	  
	  
44 
15. Tsybalova, LM, Stepanova, LA, Kuprianov, V, Blokhina, EA, Potapchuk, M, Korotkov, 
A, et al. (2015). Development of a candidate influenza vaccine based on virus-like 
particles displaying influenza M2e peptide into the immunodominant region of hepatitis B 
core antigen: Broad protective efficacy of particles carrying four copies of M2e. Vaccine 
33: 3398–3406. 
16. Neirynck, S, Deroo, T, Saelens, X, Vanlandschoot, P, Jou, WM and Fiers, W (1999). A 
universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. 
Med. 5: 1157–1163. 
17. Kim, OY, Hong, BS, Park, KS, Yoon, YJ, Choi, SJ, Lee, WH, et al. (2013). Immunization 
with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 
and Th17 cell responses. J. Immunol. 190: 4092–102. 
18. Rosenthal, JA, Huang, C, Doody, AM, Leung, T, Mineta, K, Feng, DD, et al. (2014). 
Mechanistic insight into the Th1-biased immune response to recombinant subunit vaccines 
delivered by probiotic bacteria-derived outer membrane vesicles. PLoS One 9: e112802. 
19. Kim, JY, Doody, AM, Chen, DJ, Cremona, GH, Shuler, ML, Putnam, D, et al. (2008). 
Engineered bacterial outer membrane vesicles with enhanced functionality. J. Mol. Biol. 
380: 51–66. 
20. Chen, DJ, Osterrieder, N, Metzger, SM, Buckles, E, Doody, AM, DeLisa, MP, et al. 
(2010). Delivery of foreign antigens by engineered outer membrane vesicle vaccines. 
Proc. Natl. Acad. Sci. U. S. A. 107: 3099–104. 
21. Hamilton, BS, Chung, C, Cyphers, SY, Rinaldi, VD, Marcano, VC and Whittaker, GR 
(2015). Inhibition of influenza virus infection and hemagglutinin cleavage by the protease 
inhibitor HAI-2 450: 1070–1075. 
22. De Filette, M, Jou, WM, Birkett, A, Lyons, K, Schultz, B, Tonkyro, A, et al. (2005). 
Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149–
161. 
23. Liu, W, Zou, P, Ding, J, Lu, Y and Chen, YH (2005). Sequence comparison between the 
extracellular domain of M2 protein human and avian influenza A virus provides new 
information for bivalent influenza vaccine design. Microbes Infect. 7: 171–177. 
24. Kim, M-C, Lee, J-S, Kwon, Y-M, Eunju, O, Lee, Y-J, Choi, J-G, et al. (2013). Multiple 
heterologous M2 extracellular domains presented on virus-like particles confer broader 
and stronger M2 immunity than live influenza A virus infection. Antiviral Res. 99: 328–
335. 
25. Kim, MC, Song, JM, Eunju, O, Kwon, YM, Lee, YJ, Compans, RW, et al. (2013). Virus-
like particles containing multiple M2 extracellular domains confer improved cross-
protection against various subtypes of influenza virus. Mol. Ther. 21: 485–492. 
26. Watanabe, H, Numata, K, Ito, T, Takagi, K and Matsukawa, A (2004). Innate immune 
response in Th1- and Th2-dominant mouse strains. Shock 22: 460–466. 
 	  
	  
45 
27. Lee, YN, Kim, MC, Lee, YT, Hwang, HS, Cho, MK, Lee, JS, et al. (2014). AS04-
adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza 
virus confer improved protection. Vaccine 32: 4578–4585. 
28. Ibañez, LI, Roose, K, De Filette, M, Schotsaert, M, De Sloovere, J, Roels, S, et al. (2013). 
M2e-displaying virus-like particles with associated RNA promote T helper 1 type 
adaptive immunity against influenza A. PLoS One 8. 
29. Kim, MC, Lee, YJYN, Ko, EJ, Lee, JS, Kwon, YM, Hwang, HS, et al. (2014). 
Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes 
strain specificity and provides long-term cross protection. Mol. Ther. 22: 1364–74. 
30. Fiers, W, De Filette, M, Birkett, A, Neirynck, S and Min Jou, W (2004). A “universal” 
human influenza A vaccine. Virus Res. 103: 173–176. 
31. Maisonneuve, C, Bertholet, S, Philpott, DJ and De Gregorio, E (2014). Unleashing the 
potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. 
A. 111: 1–6. 
32. Kuehn, MJ and Kesty, NC (2005). Bacterial outer membrane vesicles and the host – 
pathogen interaction. Genes Dev.: 2645–2655doi:10.1101/gad.1299905.negative. 
33. Adler-Moore, J, Munoz, M, Kim, H, Romero, J, Tumpey, T, Zeng, H, et al. (2011). 
Characterization of the murine Th2 response to immunization with liposomal M2e 
influenza vaccine. Vaccine 29: 4460–4468. 
34. Ernst, WA, Kim, HJ, Tumpey, TM, Jansen, ADA, Tai, W, Cramer, D V., et al. (2006). 
Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 
epitope vaccines. Vaccine 24: 5158–5168. 
35. Deng, L, Cho, JK, Fiers, W and Saelens, X (2015). M2e-Based Universal Influenza A 
Vaccines. Vaccines 3. 
36. Wu, F, Yuan, XY, Li, J and Chen, YH (2009). The co-administration of CpG-ODN 
influenced protective activity of influenza M2e vaccine. Vaccine 27: 4320–4324. 
37. Ravin, N, Blokhina, E, Kuprianov, V, Stepanova, L, Shaldjan, A, Kovaleva, A, et al. 
(2015). Development of a candidate influenza vaccine based on virus-like particles 
displaying influenza M2e peptide into the immunodominant loop region of hepatitis B 
core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective 
effici. Vaccine 33: 3392–3397. 
38. Fan, J, Liang, X, Horton, MS, Perry, HC, Citron, MP, Heidecker, GJ, et al. (2004). 
Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and 
rhesus monkeys. Vaccine 22: 2993–3003. 
39. Kaparakis-Liaskos, M and Ferrero, RL (2015). Immune modulation by bacterial outer 
membrane vesicles. Nat. Rev. Immunol. 15: 375–387. 
 
 	  
	  
46 
40. Duthie, MS, Windish, HP, Fox, CB and Reed, SG (2011). Use of defined TLR ligands as 
adjuvants within human vaccines. Immunol. Rev. 239: 178–196. 
 	  
	  
47 
CHAPTER 3 
INVESTIGATION OF LIPID IVA RECOMBINANT OUTER MEMBRANE VESICLES AS A 
SAFE AND EFFICACIOUS ADJUVANT PLATFORM 
Introduction 
There is high demand for tailored vaccine adjuvants that can elicit directed immune responses 
against protein-based antigens1. Traditionally, vaccines are made from inactivated or live 
attenuated pathogens.  While inactivated and live attenuated vaccines often offer the longest 
immune memory and protection, they are not suitable for all pathogens due to safety concerns, 
such as the possibility of reversion and contraindications for use in immune-compromised 
patients.  Recombinant subunit vaccines and virus like particles (VLP) are attractive alternative 
design choices, as they induce immunity to pathogen-derived antigens in the absence of the 
pathogen itself.  However, unlike inactivated or live attenuated vaccines, which retain inherent 
immunogenicity from the pathogen, recombinant subunit vaccines often require an adjuvant to 
generate a sufficient immune response and to appropriately direct the immune system2. 
Recombinant E. coli-derived outer membrane vesicles (rOMVs) are a naturally self-adjuvanting 
and unique pathogen mimetic vaccine platform that represent a link between inactivated vaccines 
and subunit vaccines. rOMVs are shed from hypervesiculating strains of E coli,  resulting in 
vesicles that contain pathogen associated molecular patterns (PAMPs), but are noninfectious3,4.  
The hypervesiculating E. coli strains are transformed with a plasmid encoding an antigen of 
interest genetically fused to a transmembrane protein, resulting in antigen transport to the outer 
membrane of E. coli and subsequent display on rOMVs5.  Previously, rOMV vaccines proved 
capable of generating strong immune responses to antigens of interest displayed on their surface 
and in inducing protection against bacterial and viral pathogens, demonstrating their potential as 
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a vaccine platform6–9.   
While rOMV-based vaccine platforms shows significant promise, their 
lipopolysaccharide (LPS) content hampers clinical translation10,11. LPS is a potent adjuvant that 
stimulates through toll like receptor 4 (TLR4), but high levels can lead to fever, inflammation, 
and septic shock12.   Modification to the lipid A region of LPS can greatly impact its ability to 
interact with TLR4 and increase the safety of LPS as an adjuvant. lpxM knockout E. coli strains, 
which produce pentacylated LPS instead of hexacylated LPS, were previously used to generate 
rOMVs with attenuated LPS toxicity6,13. However, rOMVs containing only the LPS precursor 
lipid IVa, which is a human TLR4 antagonist, have not yet been generated or reported. Unlike 
LPS, lipid IVa is an antagonist to human TLR4, though it does still retain some ability to 
stimulate murine TLR414. The E. coli strain, BL21(DE3) (BL21), was recently engineered to 
contain only lipid IVa instead of full LPS. This strain, KPM404, sold as ClearColi® (CC), is 
marketed by Lucigen as an endotoxin-free E. coli strain for use in recombinant protein 
production15. Despite containing only lipid IVa, we hypothesized that CC-derived rOMVs would 
retain sufficient intrinsic PAMPs to generate equivalent immunity against displayed exogenous 
proteins, but with greatly reduced pyrogenicity and toxicity when compared to LPS unmodified 
rOMVs 
Here, we report a retooling of the rOMV adjuvant platform that significantly reduces 
endotoxicity while maintaining adjuvant potential, thereby opening the opportunity of rOMVs to 
translate into the clinic. We engineered CC to hypervesiculate and compared the ability of CC 
rOMVs vs. the parent strain BL21- derived rOMVs to trigger immune responses both in vivo and 
in vitro.  Additionally, we directly compared the immune responses of CC rOMVs to E. coli 
Nissle 1917 (Nsl) rOMVs, which previously demonstrated superior immunomodulatory 
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properties relative to rOMVs derived from E. coli K12 strains6.  Finally, we evaluated the 
efficacy of CC rOMVs to protect against influenza challenge in mice of three genetic 
backgrounds (BALB/c, C57BL/6 and DBA/2J) as well as in the more clinically relevant ferret 
model against human pandemic H1N1 influenza.  Collectively, our results demonstrate that CC 
rOMVs offer significantly improved safety over other rOMV E. coli source strains investigated 
herein, and maintain the rOMV benefits of potent immune responses. 
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Materials and methods  
Strain engineering to induce hypervesiculation 
Hypervesiculating, nlpI knockout E. coli strains were constructed using phage transduction and 
the KeiO collection as previously described57,58.  Briefly, E. coli donor strain MC4100 ΔnlpI kanr 
was subcultured 1:100, then infected with P1 phage for 6h.  Phage was collected and used to 
infect ClearColi® (Lucigen, Middleton, WI) and BL21(DE3) (New England Biolabs, Ipswich, 
MA) for 1.5 h. Bacteria were centrifuged and plated on kanamycin (50 µg/mL) plates to select 
for ΔnlpI  knockouts. Gene knockout was confirmed via PCR using primers nlpI-F and nlpI-R 
(Table S1) followed by sequencing and analysis using the Basic Local Alignment Search Tool 
(BLAST). To ensure strain contamination had not occurred during the knock out process, 
ClearColi® ΔnlpI was sequenced with gutQ-F and gutQ-R to verify absence of gene gutQ (Table 
S1)15.   
 
Recombinant OMV production and characterization 
E. coli strains CC and BL21 were transformed with a pBAD plasmid expressing ClyA-GFP, as 
described by Kim et al5.  E. coli strains CC and Nsl were transformed with a pBAD plasmid 
expressing ClyA-M2e4xHet, as described by Rappazzo et al10.  Transformed strains were grown 
overnight (ON) in LB broth (Thermo Fisher Scientific, Waltham, MA) at 37° C then subcultured 
to OD600 = 0.08.  Strains were induced with 2% L-arabinose (Sigma-Aldrich, St. Louis, MO) at 
OD600 = 0.55 and grown for 18 more hours. Subsequently, bacteria were centrifuged (4° C, 15 
minutes, 5000 rcf) and passed through a 0.2 µm filter.  The filtrate was ultracentrifuged (26k 
rpm, 4 °C, 3h) then decanted and the pellets suspended in sterile phosphate buffered saline 
(PBS). rOMV samples were aliquoted and stored at -20° C until use.  rOMV surface protein 
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content was determined using a BCA assay (Thermo Fisher Pierce, Waltham, MA) and antigenic 
content determined via Western blot (WB). To detect ClyA-GFP, polyclonal anti-GFP antibody 
was used (Life Technologies, Carlsbad, CA) and to detect ClyA-M2e4xHet, anti-His (clone HIS-
1) antibody (Sigma-Aldrich, St. Louis, MO) was used. Western blots (WB) were developed 
using chemiluminescence and imaged with ChemiDoc Touch Imaging System (Bio-Rad, 
Hercules, CA). Semi-quantitative analysis of WB demonstrated that 2% of total protein in Cly-
GFP rOMVs was GFP and that ~6% of total protein in ClyA-M2e4xHet rOMVs was M2e4xHet 
(Figure S1a,b). TEM samples were prepared by negatively staining with 2% uranyl acetate on 
copper grids then imaged with a FEI T12 Spirit TEM. 
 
Whole blood pyrogen testing 
The protocol for the pyrogen test was adapted from Daneshian et al18.  Donor blood was 
collected into a heparinized tube and rotated at room temperature until use (maximum time did 
not exceed 2h).  Endotoxin-free 96 well tissue culture plates were filled with 200 µL of 
endotoxin-free saline, into which 20 µL of blood was added, along with 20 µL of rOMVs, 20 µL 
of lipid IVa (Carbosynth, Compton, UK), or 20 µL of E-toxate endotoxin standard (Sigma-
Aldrich, St. Louis, MO).  Endotoxin standard curve ranged from 10 EU/mL to 0.125 EU/mL.  
Lipid IVa and rOMV samples were serially diluted by 10 (from 10 µg/mL to 0.001 pg/mL), 
plated in quadruplicate, and incubated (37° C, 18h). Subsequently, samples were centrifuged 
(500 rcf, 5 minutes, RT) and supernatant collected.  An IL-1β sandwich ELISA was performed 
on each supernatant, following the protocol from Biolegend (San Diego, CA).  Plates were pre-
coated with 2 µg/mL of anti IL-1β (clone H1b-27, Biolegend, San Diego, CA) in PBS overnight 
at 4° C. Plates were blocked (1% BSA, 1h, RT), incubated with 100 µL of supernatant per well 
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(2h, 37° C), coated with anti-IL-1β biotin (clone H1b-98, Biolegend, San Diego, CA) (1h, RT), 
coated with avidin-HRP (Sigma-Aldrich, St. Louis, MO) (30 min RT), then developed with 
3,3,5,5-tetramethylbenzidine (TMB) in the dark for 20 minutes.  The reaction was stopped with 
4N H2SO4 and absorbance read at 450 nm.  The plates were washed at least 3x with wash buffer 
(0.3% bovine serum albumin + 0.05% Tween-20 in PBS) between each step.  A 4 parameter 
logistic curve was fitted to the log of the endotoxin standard vs. the standard absorbances using 
Prism6 software (GraphPad software, La Jolla, CA).  All blood donors gave written, informed 
consent, and the protocol for blood collection and use was approved by Cornell University’s 
Institutional Review Board.  
 
In vitro pathogen recognition receptor studies 
HEK-BlueTM KD-TLR5 cells (InvivoGen, San Diego, CA), which lack expression of all TLRs 
except TLR1 and TLR6, were transfected with individual human or mouse TLRs and stimulated 
with TLR ligands overnight, as previously described10. Cells were grown in complete DMEM 
media comprised of the following: DMEM media (Corning, Corning, NY), supplemented with 
10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 U/mL penicillin, 50 U/mL 
streptomycin, and 10% heat inactivated low endotoxin fetal bovine serum (FBS) (VWR Life 
Science Seradigm, Radnor, PA). Subsequently, media was assayed for secreted alkaline 
phosphatase activity using Quanti-blue (InvivoGen, San Diego, CA). 20 µL of each sample was 
added to 200 µL of Quanti-blue, incubated (37° C, 3 h), and then read at absorbance of 630 nm. 
For sensitive chemiluminescence assay, cells were transfected with the following: 5xNF-kβ-
luciferase reporter plasmid and either murine MD-2, murine CD14, and murine TLR4 plasmids 
(Invivogen, San Diego, CA) or human MD-2, human CD14, and human TLR4 plasmids 
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(Invivogen, San Diego, CA). Cells were stimulated with ligands overnight, and lysed (Reporter 
Lysis 5x Buffer, Promega, Madison, WI).  Luciferase activity was quantified by addition of 100 
µL D-luciferin substrate to 20 µL of lysate and read using a Veritas luminometer (Promega, 
Madison, WI). NOD signaling assays were carried out using HEK-BlueTM mNOD1 and mNOD2 
reporter cells (InvivoGen, San Diego, CA).  Cells were plated at 0.28 x 106 cells/mL (NOD1) or 
0.23 x 106 cells/mL (NOD2) and incubated (37° C, 48 h) with 10 µg/mL positive control (NOD1: 
γ-D-glutamyl-meso-diaminopilemic acid (iE-DAP), NOD2: muramyl dipeptide (MDP), 
Invivogen, San Diego, CA), negative control (PBS), and rOMVs (100 ng/mL).  Supernatant was 
subsequently collected and analyzed using Quanti-blue (InvivoGen, San Diego, CA). 
 
BMDC isolation and maturation 
Methods for generating bone marrow-derived dendritic cells (BMDCs) were adapted from Lutz 
et al59. Femurs were harvested from three 12-week-old C57BL/6 mice and three 12-week-old 
BALB/c mice (Jackson Laboratories, Bar Harbor, ME) and subsequently kept separate 
throughout the culturing process.  Femurs were flushed with RPMI 1640 media (Corning, 
Corning, NY) and the resulting cell suspension centrifuged (400 g, 5 min, 4° C) and resuspended 
2x using RPMI 1640 media. Cells were cultured in Petri dishes (Corning, Corning, NY) at 1x106 
cells/mL in RPMI 1640 media supplemented with 10% low endotoxin heat inactivated FBS, 2 
mM L-glutamine, 50 U/mL penicillin, 50 U/mL streptomycin, 50 nM 2-mercaptoethanol, and 20 
ng/mL of recombinant granulocyte macrophage colony-stimulating factor (GM-CSF, R&D 
Systems, Minneapolis, MN). Half of the media was removed and replaced with fresh media on 
days 3 and 6 post harvest.  On day 7, all non-adherent and loosely adherent cells were harvested 
and plated in 6 well plates (Corning, Corning, NY)  (2 mL/plate), then dosed with 100 ng/mL of 
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CC or Nsl rOMVs, or 100 ng/mL LPS. Cells were harvested for flow cytometry staining 24 h 
after dosing using 50 mM ethylenediaminetetraacetic acid (EDTA) in PBS. Cells were Fc 
blocked (Mouse BD Fc BlockTM, BD, Franklin Lakes, NJ) and stained for viability (Ghost 
DyeTM Violet 510 viability dye, Ex:405, Em:510) (15 min, 4° C, in dark). Next, cells were 
surface stained for CD11c (violetFluorTM 450, Ex:405, Em:450), CD86 (PE, Ex:496, Em:578), 
and MHCII (redFluorTM 710, Ex:633-647, Em:710) (Tonbo biosciences, San Diego, CA) (30 
min, 4° C, in dark). Cells were then fixed (10% formaldehyde, 15 min, 4° C, in dark), 
resuspended in 1% FBS in PBS, and analyzed using flow cytometry.  Data was collected using a 
LSR II flow cytometer and analyzed with FCS Express. DCs were gated on live, CD11cHi cells. 
Mature DCs were identified as MHCIIHi, CD86Hi cells. Concentration of cytokines IL-12p70, IL-
10, TNF-α, and IL-6 in sample supernatants was determined by ELISA kits according to 
manufacturer instructions (R&D Systems, Minneapolis, MN).  To determine the amount of type 
1 IFN in supernatant, L929-ISRE cells were plated at 1x105 cells/well in a 96 well plate using 
complete DMEM.  Cells were allowed to settle overnight, then media was removed and replaced 
with 50 µL of either DC supernatant or complete DMEM with IFN standards.  Cells were 
incubated with these samples for 4 hours, then supernatant removed, cells lysed (Reporter Lysis 
5x Buffer, Promega, Madison, WI), and luminescence measured using same procedure as 
described above for the transfected HEK-BlueTM KD-TLR5 cells.   
 
Mouse immunization 
For the GFP trial, 10-week-old female BALB/c mice bred at Cornell University were 
subcutaneously injected with a prime dose of 20 µg ClyA-GFP CC rOMVs (n=5), 20 µg ClyA-
GFP BL21 rOMVs (n=5), or 100 µL phosphate buffered saline (PBS) (n=3).  All mice received a 
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boost dose of the same composition as the prime dose 4 weeks later.  For the influenza trials, 7-
week-old female BALB/c, C57BL/6, and DBA/2J mice (Jackson Laboratories, Bar Harbor, ME) 
were subcutaneously injected with 40 µg (total surface protein) ClyA-M2e4xHet CC rOMVs in 
100 µL PBS (n=11 BALB/c, n=10 C57BL/6, n=5 DBA/2J), 40 µg (total surface protein) ClyA-
M2e4xHet Nsl rOMVs in 100 µL PBS (n=12 BALB/c), or 100 µL PBS (n=16 BALB/c, n=10 
C57BL/6, n=5 DBA/2J).  Four weeks post prime injection, a boost dose of the same composition 
was administered.  All mice were weighed and observed daily following the prime (BALB/c, 
C57BL/6) and boost (BALB/c) injections. An additional cohort of mice, referred to as ‘pre-
exposed’, was immunized at age 8 weeks via intranasal injection of 5 FFU of influenza A/PR8 
(n=9 BALB/c, n=8 C57BL/6) to give them immunity to the PR8 virus and allow them to serve as 
a positive vaccination control.  All mouse work was approved by Cornell’s Institutional Animal 
Care and Use Committee.   
 
Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were performed as previously described6,10.  Briefly, Nunc Maxisorp plates (Nalge 
Nunc, Rochester, NY) were coated (2 µg/mL GFP, 12h, 4° C or 2 µg/mL M2e peptide 
(SLLTEVETPIRNEWGSRSNDSSD) (LifeTein, Somerset, NJ), 12h, 37° C), blocked (5% milk 
in PBS, 1h, 25° C), then incubated with 2-fold serial dilutions of serum plated in triplicate (2h, 
37°C). Plates were subsequently incubated with biotin-conjugated antibody (1:10000 dilution, 
IgG, IgG1, or IgG2a) (eBiosciences, San Diego, CA) (1h, 37° C), incubated with HRP-avidin 
(1:10000 dilution, 0.5h, 37° C), developed in the dark for 20 minutes with TMB (Thermo Fisher 
Scientific, Waltham, MA), then stopped with 4N H2SO4 and absorbance read at 450 nm. The 
plates were washed at least 3x with wash buffer (0.3% bovine serum albumin + 0.05% Tween-20 
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in PBS) between each step.  Titers were determined as the highest dilution in which the sample 
gave a signal greater than the average of naïve serum at the same dilution plus three times the 
standard deviation of the naïve serum.   
 
Mouse influenza challenge 
Influenza A/Puerto Rico/8/1934 (PR8) virus (BEI Resources, Manassas, VA) was used to 
challenge BALB/c and C57BL/6 mice in the influenza vaccine trial.  Previously, the PR8 stock 
was titered via fluorescent forming units (FFU) assay10.  PR8 was diluted in PBS for use in 
exposure vaccination of the pre-exposed positive control mice and for use in the lethal 
challenges.  All mice were challenged 10 weeks post their prime vaccination (for both 
subcutaneously injected and pre-exposed mice).  Mice were administered 50 µL via intranasal 
injection of diluted PR8 while under isofluorane anesthesia (5 FFU for exposure vaccination of 
BALB/c and C57BL/6, 50 FFU for lethal challenge of BALB/c (~2.5x LD50), 100 FFU for lethal 
challenge of C57BL/6 (~2.5x LD50).  100 FFU was selected for lethal challenge of C57BL/6 
mice, as preliminary dosing studies indicated C57BL/6 mice were less sensitive than BALB/c to 
PR8.  Influenza A virus reassortant X-47 (A/Victoria/3/1975 (HA, NA) x A/Puerto Rico/8/193 
(H3N2)) (BEI Resources, Manassas, VA) was used to challenge DBA/2J mice.  Virus was grown 
in embryonated eggs, then collected and titered via plaque forming unit (PFU) assay, as 
previously described60.  Mice were weighed daily and observed twice daily following influenza 
infection. Any mouse with more than 30% weight loss, or exhibiting signs of severe distress, was 
humanely euthanized. All mouse work was approved by Cornell’s Institutional Animal Care and 
Use Committee.   
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Ferret immunization and challenge 
Three groups of 6 male Fitch ferrets (Triple F Farms, Sayre, PA) that were 7 months of age and 
serologically negative by hemagglutination inhibition (HI) for currently circulating influenza 
viruses were used for this study.  Ferrets were housed in a Duo-Flo Bioclean Unit (Lab Products 
Incorporated, Seaford, DE) throughout the study and were intramuscularly vaccinated twice with 
either 500 µL (1.5 mg total surface protein) of ClyA-M2e4xHet CC rOMV, 500 µL (1.5 mg total 
surface protein) of CC rOMV that did not contain the pBAD plasmid (Mock-rOMV) or 500 µL 
of Fluvirin (2015-2016 formula, Norvartis Vaccines and Diagnostics Limited, Cambridge, MA) 
at four week intervals for primary and boost vaccinations. Body temperature and local 
inflammation at the injection site (biceps femoris of caudal thigh) were monitored daily for 3 
days post vaccination. Serum samples were collected on day 28 (pre-boost) and on day 56 (pre-
challenge) after primary vaccination for antibody titer determination. Ferrets were intranasally 
challenged 35 days after the boost vaccination with 1 mL of 106 PFU of A/California/7/2009 
virus (pdmH1N1) virus diluted in PBS following anesthesia with ketamine-xylazine-atropine 
cocktail injection. Three ferrets from each group were observed daily for clinical signs of 
disease, weight loss and lethargy as described previously61. The remaining three ferrets were 
euthanized on day 3 p.c. so that nasal washes and respiratory tissues (nasal turbinate, trachea and 
lung) could be collected to evaluate viral replicative ability in the respiratory tract of ferrets by 
titrating samples in eggs.  All animal experiments were performed under the guidance of the 
Centers for Disease Control and Prevention’s Institutional Animal Care and Use Committee in 
an Association for Assessment and Accreditation of Laboratory Animal Care International-
accredited facility. 
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Statistics 
Groups in the pyrogenicity assay were compared with the Kruskal-Wallis test, followed by 
Mann-Whitney between pairs, using Bonferroni method to account for multiple comparisons. 
TLR/NOD signaling data, dendritic cell maturation marker data, cytokine production data, and 
mouse weight loss data were analyzed using an ANOVA, followed by multiple comparisons with 
respect to control using Dunnett’s method of correction.  Average titer values were calculated by 
taking the geometric mean of the titers in each cohort. IgG ELISA titer data were compared 
between two groups using a two-sided Student’s t-test on log-transformed data.  IgG1 and 
IgG2a/IgG2c titer data was analyzed using a paired two-sided Student’s t-test on log-transformed 
data. Kaplan-Meier survival curves were analyzed with a log-rank test using a Bonferroni-
corrected alpha to account for multiple comparisons. All statistical analyses were conducted 
using Prism6 software (GraphPad software, La Jolla, CA).  
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Results 
Antigen expressing ClearColi® and BL21(DE3) rOMVs produce and display equivalent in 
vivo immunogenicity 
ClearColi® (CC) and its parent strain, BL21(DE3), were engineered to hypervesiculate through 
knock out of nlpI, which is known to induce increased vesiculation in laboratory strains of E. 
coli16,17.  rOMVs were imaged using transmission electron microscopy (TEM) and demonstrated 
similar morphology and size (50-100 nm) to rOMVs produced by the previously reported E. coli 
strain Nissle 1917 (Nsl) (Figure 1A-C)10. CC and BL21 were further modified by transformation 
with plasmids carrying the gene for transmembrane protein cytolysin A (ClyA) fused to GFP5.  
Western blot confirmed that the rOMVs contained ClyA-GFP (Figure S1a).  
To provide a direct assessment of the role LPS plays in eliciting a humoral response 
against rOMV displayed proteins, 10-week-old BALB/c mice were injected with 20 µg ClyA-
GFP displaying rOMVs derived from either CC (n=5) or BL21 (n=5), then given an equivalent 
boost dose 4 weeks later.  Humoral immune response to the rOMV vaccines was evaluated using 
serum from 8 weeks post prime injection and measuring the anti-GFP titers of total IgG and IgG 
isotypes.  Both CC and BL21 ClyA-GFP rOMV vaccinated mice developed high total IgG titers, 
and the geometric mean of anti-GFP titers elicited by CC did not vary significantly from those 
elicited by BL21 (p>0.05) (Figure 1d).  The serum was further analyzed for IgG1 and IgG2a 
isotype titers to assess immune system bias and found a balanced IgG1:IgG2a ratio generated by 
both CC and BL21 rOMVs (Figure 1e).  Therefore, although the CC rOMVs contained only 
lipid IVa, they were able to elicit a strong anti-GFP humoral immune response that was 
equivalent to that of their parent strain, BL21, which contained unmodified LPS.   
  
 	  
	  
60 
 
 
 
Figure 1. rOMVs produced from 3 different E. coli strains are structurally 
comparable. (a-c) TEM images of rOMVs stained with uranyl acetate: CC 
rOMVs (a), BL21 rOMVs (b), Nsl rOMVs (c).  Scale bar represents 100 
nm.  (d, e) Total IgG (d) and isotypes IgG1 and IgG2a (e) anti-GFP titers 
from BALB/c mice 8 weeks post prime dose of ClyA-GFP expressing CC 
or BL21 rOMVs. Titer error bars represent 95% confidence intervals (C.I.) 
of geometric mean. Log-transformed data analyzed using an unpaired 
Student’s t-test to compare CC vs. BL21 rOMV anti-GFP IgG levels and 
using a paired Student’s t-test to compare IgG1:IgG2a levels for each 
rOMV type.  Dotted line indicates titer of sera from mice pre-vaccination. 
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ClearColi® derived rOMVs have greatly reduced pyrogenicity than parent strain rOMVs 
The investigational aim for CC rOMVs was to reduce the toxicity associated with high doses of 
rOMVs, while retaining the benefits of a pathogen mimetic particle. As CC rOMVs displayed 
equivalent capability to BL21 in generating anti-GFP titers, we sought to determine whether CC 
rOMVs had significantly reduced pyrogenicity relative to rOMVs derived from BL21 or Nsl 
strains using a whole blood pyrogenicity test. In this test, the response of blood monocyte 
interactions with pyrogens is quantified by IL-1β release, which is then related to a standard 
endotoxin curve18.  Thus, the readout for the whole blood pyrogen test is endotoxin units (EU), 
though the test measures all pyrogens present and not just endotoxin (LPS).  This test is 
performed using human blood, as humans have enhanced endotoxin and pyrogen sensitivity 
relative to mice19. CC rOMVs generated a response that was 105 - 106 fold lower than BL21 
rOMVs and Nsl rOMVs, highlighting the impact that lipid IVa, as opposed to full LPS, has on 
reducing the overall toxicity (Figure 2a). Pure lipid IVa at a concentration of 10 µg/mL 
generated a response that was beneath detection by the IL-1β ELISA, confirming that it alone is 
not pyrogenic.  The assay highlights that while CC rOMVs have significantly reduced 
pyrogenicity compared to other OMV types, they are not completely pyrogen free.  
 
ClearColi® rOMVs stimulate through TLR2 
The ability of CC rOMVs to generate equivalent immune titers as BL21 rOMVs led us to 
investigate their ability to trigger pathogen recognition receptors (PRRs) other than toll-like 
receptor 4 (TLR4), of which LPS is a known agonist.  First, rOMVs were used to stimulate a 
panel of TLR transfected reporter cells, leading to NF-kβ activation; cells transfected with TLR4 
were also always transfected with species specific MD-2 and CD14. Both murine (m) and human 
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TLRs were tested (Figures 2b,c; S2a-c). As expected, Nsl rOMVs signaled predominantly 
through murine and human TLR2 and TLR4, human TLR5, and murine TLR11, as was 
previously described10.  BL21 rOMVs also stimulated TLR2 and TLR4; however, BL21 lack 
flagellin and thus did not stimulate TLR5 (Figures 2b,c; S2a-c)20.  Similar to BL21, CC also 
does not make flagellin and lacks activity against TLR5 (S2c). Unlike Nissle and BL21, CC 
showed no activity for human TLR4 (Figures 2c).  CC did stimulate murine TLR4, though to a 
level significantly lower than either the BL21 or Nsl rOMVs.  This is unsurprising, as it is 
reported that lipid IVa is a moderate agonist of murine TLR4, but an antagonist of human TLR4 
21,22.  CC exhibited activity against both murine and human TLR2, indicating TLR2 stimulation 
might contribute to CC pyrogenicity  (Figures 2 b). None of the rOMVs showed activity against 
any of the other tested murine or human TLRs (Figures S2a-b).  Nucleotide-binding 
oligomerization domain (NOD) receptors are intracellular sensors of bacteria, which detect 
motifs found in peptidoglycan23.  Neither CC nor BL21 rOMVs caused a response in NOD1 or 
NOD2 reporter cells (S2d,e). While Nsl rOMVs did stimulate NOD1 and NOD2, the NOD1 and 
NOD2 reporter cell lines endogenously express TLR5, indicating that flagellin was likely 
responsible for their activation.  While possible that CC rOMVs stimulate PRRs that were not 
tested, the data suggests that the immunogenicity of CC rOMVs is likely driven primarily by 
their TLR2 agonist activity.   
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Figure 2. (a) Pyrogenicity (measured in endotoxin units, EU) of CC, Nsl, and BL21 rOMVS 
determined using whole blood pyrogenicity test. Groups were compared with Kruskal-Wallis 
test, followed by Mann-Whitney between pairs, using Bonferroni method to account for multiple 
comparisons (* p<0.01). Error bars represent 95% CI of geometric mean (n=5 blood donors). (b) 
HEK-BlueTM KD-TLR5 cells transfected with human TLR2 or mTLR2 were stimulated with 
rOMVs (100 ng/mL) or Pam3Cys (1 µg/mL, (+) CTL) for 16 h. (c) HEK-BlueTM KD-TLR5 cells 
transfected with 5xNF-kβ-luciferase reporter and TLR4/MD-2/CD14 or mTLR4/mMD-
2/mCD14 were stimulated with rOMVs (100 ng/mL), lipid IVa (100 ng/mL), or LPS (100 
ng/mL, (+) CTL) for 16 h.  Samples analyzed by ANOVA followed by multiple comparisons 
against media using Dunnett method of correction (* p<0.0001).  Error bars represent standard 
deviation (n=4).   
 
ClearColi® rOMVs promote dendritic cell maturation 
Dendritic cells (DCs) play a key role in directing the immune system and help to facilitate bias 
towards a Th1 or Th2 type response24.  Production of IL-12p70 by DCs triggers production of 
IFN-γ by Th1 cells, cytotoxic T cells, and NK cells25. It is well established that LPS matures DCs 
and promotes a Th1 bias; therefore, we next asked if the outer membrane composition of the 
lipid IVa-containing CC rOMVs could lead to maturation of DCs26.  We compared the cytokines 
produced from bone marrow-derived dendritic cells (BMDCs) stimulated by CC and Nsl rOMVs 
to determine if one rOMV type was more prone to eliciting a Th1 bias. We focused our 
comparison on CC rOMVs vs. Nsl rOMVs, as there is precedent for Nsl rOMVs being used in 
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protective rOMV vaccines6,10.  Immature BMDCs from BALB/c or C57BL/6 mice were 
incubated with CC rOMVs, Nsl rOMVs, LPS (positive control) or PBS (negative control) for 24 
h or 48h. Both CC rOMVs and Nsl rOMVs resulted in significant and equivalent BMDC 
maturation in both BALB/c and C57BL/6 mice, as indicated by upregulation of maturation 
markers CD86 and MHCII (Figures 3a-c). Supernatants from the stimulated and unstimulated 
BMDCs were collected and measured for IL-10, IL-12p70, Type 1 IFN, IL-6, and TNF-α 
(Figures 3d-h, S3a-f).  Production of IL-12p70 is associated with a Th1 biased inflammatory 
response, whereas production of IL-10 is associated with a suppressive immune response27.  
Treating BMDCs with rOMVs did not increase IL-10 production relative to the control PBS 
treated cells, except in the 24h time point of BALB/c BMDCs treated with CC rOMVs. 
However, by 48h, the difference in IL-10 levels between PBS and CC rOMV treated BALB/c 
BMDCs was no longer significant (Figure S3a). This observed decrease in IL-10 production 
suggests sustained BMDC activation at 48h, as mature BMDCs lose sensitivity to IL-10 
signaling, which is known to stimulate IL-10 production28. IL-12p70 levels were significantly 
elevated after treatment with both CC and Nsl rOMVs in BALB/c mice, but were significantly 
elevated only after treatment with Nsl rOMVs in C57BL/6 mice. CC rOMV treatment of 
C57BL/6 BMDCs did result in an increase in IL-12p70 production, but the difference was not 
significant.  As expected, treatment with LPS led to significant production of IL-12p70 in 
BMDCs from both mouse strains.  Analysis of type1 IFN, IL-6, and TNF-α at 24h post 
stimulation showed significant increases occurred after treatment with both CC rOMVs and Nsl 
rOMVs in both BALB/c and C57BL/6 mouse strains (Figures 3f-h). The presence of type 1 IFN 
and TNF-α provide further confirmation of BMDC maturation, as type 1 IFNs have an activating 
effect on immature, committed dendritic cells by stimulating the upregulation of cell surface 
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proteins MHCII and CD8629. Additionally, autocrine TNF-α has been shown to be necessary for 
the activation of BMDCs and survival of matured BMDCs.30,31 While the inflammatory 
properties of IL-6 are context-dependent, IL-6 is known to have a significant role in promoting 
and directing the adaptive immune response. IL-6 induces B-cell maturation into antibody-
secreting cells and promotes the proliferation and survival of CD4+ T-cells32. Overall, the 
equivalent levels of BMDC maturation and increased levels of IL-12p70, IL-6, type I IFN, and 
TNF-α production, indicate potent immune activation.  Only subtle differences were seen 
between mouse strains, indicating that rOMV vaccines should activate DCs in both Th2 biased 
BALB/c mice as well as Th1 biased C57BL/6 mice.   Furthermore, the presence of lipid IVa 
instead of full LPS in CC rOMVs did not impair their ability to mature and activate dendritic 
cells.   
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Figure 3. Murine bone marrow-derived dendritic cells (BMDCs) from BALB/c and C57BL/6 
mice were stimulated with Nsl rOMVs (100 ng/mL), CC rOMVs (ng/mL), LPS (100 ng/mL), or 
PBS for 0, 24, or 48 hr, then supernatants collected for cytokine analysis, and cells stained for 
DC maturation markers (stains: viability, CD11c, CD86, MHCII). Flow cytometry was used to 
determine percent mature dendritic cells (DCs) (CD86Hi, MHCIIHi) out of the total DC 
population (gated on viability, CD11cHi). (a). Representative density plots of BMDCs isolated 
from a BALB/c mouse. (b) Percent mature DCs from BALB/c mice. (c) Percent mature DCs 
from C57BL/6 mice.  (d) IL-10 concentration after 24 h stimulation. (e) IL-12p70 conc. after 24 
h stimulation. (f) Type 1 IFN conc. after 24 h stimulation. (g) IL-6 conc. after 24 h stimulation. 
(h) TNF-α conc. after 24 h stim.  Cytokine stimulation is shown for both C57BL/6 and BALB/c 
mice. Error bars represent standard deviation. Samples analyzed via ANOVA followed by Holm 
multiple comparison test * p<0.05 (n=3 mice).   
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ClearColi® rOMVs expressing influenza A antigen M2e4xHet elicit high titers without side 
effects 
The CC rOMVs containing model antigen GFP demonstrated the ability to elicit high total IgG 
anti-GFP titers and in vitro work showed this was likely due to TLR2 stimulation, leading to DC 
maturation and immune-directive cytokine secretion. With these promising results, we sought to 
test the protective efficacy of the CC rOMV platform by creating CC rOMVs that displayed an 
influenza A-based peptide, M2e4xHet, fused to ClyA. The antigen M2e4xHet contains four 
variants of the influenza A virus matrix 2 protein separated by glycine/serine linkers (peptide 
sequence:SLLTEVETPIRNEWGSRSNDSSDgggsgggSLLTEVETPTRSEWESRSSDSSDgggsg
ggSLLTEVETPTRNEWESRSSDSSDgggsgggSLLTEVETLTRNGWGSRSSDSSD)10. Western 
blot confirmed that the rOMVs contained the ClyA-M2e4xHet protein (Figure S1b).  
Previously, Nsl rOMVs displaying ClyA-M2e4xHet led to 100% protection from challenge with 
influenza A/Puerto Rico/8/1934 (PR8) (H1N1)10.  Thus, by comparing Nsl and CC M2e4xHet 
rOMVs it is possible to determine whether CC rOMVs are as effective as an established rOMV 
vaccine in eliciting titers and providing influenza protection.     
Seven-week-old BALB/c mice were immunized with CC M2e4xHet rOMVs, Nsl 
M2e4xHet rOMVs, or PBS.  Following prime and boost immunization, mice were weighed daily 
for one week to determine whether the pyrogenicity of the rOMVs was causing negative side 
effects leading to weight loss (Figures 4 a,b).  Twenty four hours post vaccination, marked 
differences were seen between mice vaccinated with Nsl rOMV and CC rOMVs; Nsl rOMV 
vaccinated mice exhibited anorexia, lethargy, and piloerection, whereas CC rOMV vaccinated 
mice maintained normal activity and appearance. Mice vaccinated with Nsl rOMVs lost a similar 
amount of weight after both prime (Figure 4a) and boost (Figure 4b) doses, whereas mice 
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vaccinated with CC rOMVs experienced no weight loss after either dose, and had an equivalent 
response to mice receiving sham PBS injections.  The lack of negative side effects in CC rOMV 
vaccinated mice vs. Nsl rOMV vaccinated mice emphasizes the increased safety profile of the 
CC rOMV vaccine. 
Eight weeks following the prime vaccine dose, anti-M2e titers were measured to assess 
humoral vaccine response.  Both CC and Nsl rOMVs generated high and equivalent total IgG 
anti-M2e titers (p>0.05), indicating potential for both to be used as vaccine adjuvants (Fig. 4c).  
Nsl rOMVs had slight, but significant (p<0.05), elevation of IgG2a over IgG1 titers, whereas CC 
rOMVs resulted in a more balanced IgG2a:IgG1 response (Fig 4d).  Though CC rOMVs did not 
lead to elevated IgG2a:IgG1 ratio, the geometric mean IgG2a titer of CC rOMV vaccinated mice 
was not significantly different from that of Nsl rOMV vaccinated mice (p>0.05). The equivalent 
anti-M2e total IgG titers generated by Nsl and CC rOMVs once again demonstrate that full LPS 
is not necessary for CC rOMVs to cause a robust humoral immune response.   
 
ClearColi® M2e4xHet rOMVs protect against lethal influenza A challenge in BALB/c mice 
Ten weeks post prime immunization, mice were challenged with a lethal dose (50 FFU) of 
influenza A strain PR8.  In addition to the rOMV vaccinated groups and the negative control 
group, which was administered phosphate buffered saline (PBS), a positive control group of pre-
exposed mice was included.  The pre-exposed mice were given a low dose (5 FFU) of PR8 virus 
8 weeks prior to the lethal (50 FFU) dose, to allow them to develop a protective immune 
response against PR8. As expected, 100% of pre-exposed mice survived (5/5) and 0% of PBS 
vaccinated mice survived (0/5) (Figure 4e).  Mice immunized with rOMVs from both Nsl and 
CC were equally protected; 80% of mice vaccinated with Nsl M2e4xHet rOMVs survived (4/5), 
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and 100% of mice vaccinated with CC M2e4xHet rOMVs survived (5/5) (Figure 4e). Though 
one mouse in the Nsl rOMV group required euthanasia due to weight loss exceeding 30% 
original body weight, the survival of mice vaccinated with Nsl and CC rOMVs was statistically 
equivalent.  The CC rOMV vaccinated mice showed reduced morbidity with respect to the PBS 
negative control group and had weight loss that was statistically equivalent to the weight loss of 
the pre-exposed mice throughout the duration of the trial (Figure 4f).  While the literature 
suggests a Th1 bias is preferred for M2e-based vaccines, as IgG2a antibodies are a correlate of 
protection, the balanced CC rOMV vaccine response generated sufficient IgG2a to elicit full 
protection from challenge33,34. The 100% survival of BALB/c mice vaccinated with CC 
M2e4xHet rOMVs demonstrates that the immune response CC rOMVs elicit is protective against 
lethal influenza challenge.   
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Figure 4. (a,b) Mice were weighed daily for one week post prime (a) and boost (b) 
immunization. Analyzed using ANOVA followed by multiple comparisons using Dunnett 
method of correction. Error bars represent standard deviation of mean (* p< 0.001).  (c,d)  Total 
IgG (c) and IgG isotypes IgG1 and IgG2a (d) anti-M2e titers of BALB/c mice 8 weeks post 
prime rOMV immunization.  Dotted line indicates lowest titer detectable above background 
(serum from PBS vaccinated mice). Log transformed IgG1 and IgG2a anti-M2e titers compared 
using paired t-test.  Error bars indicate 95% CI of geometric mean (* p< 0.05) (n=11 CC rOMV 
vaccinated mice, n=12 Nsl rOMV vaccinated mice, n=16 PBS vaccinated mice).  (e,f) Mortality 
(e) and morbidity (f) of mice challenged with a lethal dose (50 FFU) of influenza A/PR8 (n=5 
CC rOMV vaccinated, n=5 Nsl rOMV vaccinated, n=5 PBS vaccinated, n=5 pre-exposed). 
Kaplan-Meier survival curves were analyzed with a log-rank test using the Bonferroni method to 
account for multiple comparisons.  Error bars on morbidity curves represent SEM.  
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ClearColi® M2e4xHet rOMVs elicit Th1 bias in C57BL/6 mice and protect against 
influenza 
While previous studies have demonstrated protection against influenza using M2e-based antigens 
in BALB/c mice, fewer have assessed M2e-based antigens in C57BL/6 mice35–37. When Misplon 
et al. directly compared the response of BALB/c and C57BL/6 mice to M2e based vaccines, they 
found significantly lower antibody and T-cell responses in C57BL/6 mice38.  Thus, to determine 
the robustness of the M2e4xHet antigen, and ability of CC rOMVs to adjuvant in varied mouse 
strains, 10 C57BL/6 mice were given prime and boost doses of CC rOMVs containing the 
M2e4xHet antigen.  Mouse weight was tracked for three days post injection, but no weight loss 
or other side effects (lethargy, piloerection) were noted.  Four weeks post boost injection, blood 
was collected and anti-M2e titers assessed.  The anti-M2e total IgG titers were high and 
statistically equivalent to those developed by the BALB/c vaccinated mice (Figure 5a).  In 
contrast to the BALB/c mice, which developed a balanced IgG2a: IgG1 ratio, the C57BL/6 mice 
had significantly higher IgG2c titers than IgG1—several of the mice even had IgG1 levels that 
were beneath the limit of detection of the ELISA assay (Figure 5a).  IgG2c levels were 
measured instead of IgG2a, as C57BL/6 mice do not produce IgG2a and instead produce 
IgG2c39.   The mice were challenged at 10 weeks post prime dose with a lethal dose of PR8 (100 
FFU), which resulted in 100% survival of vaccinated mice and 0% survival of unvaccinated mice 
(Figure 5b). Though all CC rOMV vaccinated mice survived, they did have significant weight 
loss compared to the positive control pre-exposed mice, which were exposed to a sublethal dose 
of PR8 (5 FFU) prior to receiving a lethal dose of PR8 (Figure 5c).  The 100% protection of 
C57BL/6 mice from challenge demonstrates the versatility of the CC M2e4xHet rOMV vaccine 
in protecting mice of different genetic background from influenza A/PR8.   
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ClearColi® M2e4xHet rOMVs elicit anti-M2e IgG titers and protect DBA/2J mice in lethal 
influenza A/X-47 (H3N2) challenge 
M2e is highly conserved amongst different influenza strains; thus, mice immunized with 
M2e4xHet rOMVs should be protected from subtypes of influenza other than influenza A/PR8 
(H1N1).  To test the robustness of the M2e rOMV antigen, DBA/2J mice were immunized with 
CC M2e4xHet rOMVs or given a PBS sham injection.  DBA/2J mice are Th2 biased and share 
the same H2d major histocompatibility complex (MHC) as BALB/c mice, but are significantly 
more susceptible to many influenza types, allowing a lethal challenged to be performed using 
influenza A/X-47 (H3N2), which is typically only sublethal in BALB/c and C57BL/6 mice40,41.   
DBA/2J mice vaccinated with CC M2e4xHet rOMVs developed high levels of anti-M2e IgG 
titers and had a balanced IgG2a:IgG1 titer ratio, just as occurred in CC M2e4xHet rOMV 
immunized BALB/c mice (Figure 5d).  Following challenge with 5000 PFU influenza A/X-47, 
100% (5/5) of M2e4xHet rOMV vaccinated DBA/2J mice survived and 100% (5/5) of PBS sham 
injected mice required euthanasia (Figure 5e,f).  Thus, the survival of mice in X-47 challenge 
demonstrates that M2e4xHet rOMVs are effective at immunizing mice against influenza A 
strains of different subtypes.   
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Figure 5. (a) Total IgG and isotypes IgG1 and IgG2c titers of C57BL/6 mice 8 weeks post prime 
rOMV vaccination.  Dotted line indicates lowest titer detectable above background. Log 
transformed IgG1 and IgG2c titers compared using paired t-test.  Error bars indicate 95% C.I. of 
geometric mean (n=10 CC rOMV vaccinated mice) (* p<0.0001).  (b, c) Mortality (b) and 
morbidity (c) of mice challenged with a lethal dose (100 FFU) of influenza A/PR8 (n=5 CC 
rOMV vaccinated, n=5 PBS vaccinated, n=5 pre-exposed). Kaplan-Meier survival curves were 
analyzed with a log-rank test.  Error bars on morbidity curves represent standard error of mean. 
(d) Total IgG and isotypes IgG1 and IgG2a titers of DBA/2J mice 8 weeks post prime rOMV 
vaccination.  Dotted line indicates lowest titer detectable above background. Log transformed 
IgG1 and IgG2c titers compared using paired t-test.  Error bars indicate 95% C.I. of geometric 
mean (n=5 CC rOMV vaccinated mice) (* p<0.0001).  (e, f) Mortality (e) and morbidity (f) of 
mice challenged with a lethal dose (500 PFU) of influenza A/X-47 (n=5 CC rOMV vaccinated, 
n=5 PBS vaccinated). Kaplan-Meier survival curves were analyzed with a log-rank test.  Error 
bars on morbidity curves represent standard error of mean. 
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ClearColi® M2e4xHet rOMVs elicit anti-M2e IgG titers in ferrets and reduce virus load in 
lungs 
The mouse studies indicated that M2e4xHet CC rOMVs showed promise as an influenza 
vaccine, thus the vaccine was next evaluated in a more clinically relevant influenza animal 
model: ferrets.  Unlike mice, which typically require influenza strains to be mouse adapted, 
ferrets are naturally susceptible to both human and avian influenza viruses.  Additionally, ferrets 
infected with influenza present with fever, sneezing, and nasal discharge in addition to weight 
loss, more closely mimicking a human infection42. Three cohorts of 6 ferrets were immunized 
with either CC M2e4xHet rOMVs, CC ‘mock’ rOMVs (produced from E. coli that did not 
contain the pBAD ClyA-M2e4xHet encoding plasmid), or Fluvirin (an FDA-approved seasonal 
hemagglutinin subunit influenza vaccine).   Similar to the mouse experiments, the prime and 
boost doses were given 4 weeks apart and blood was collected 4 weeks post the boost dose.  
Following each round of vaccinations, ferret body temperature was recorded to watch for fever 
and injection sites were monitored for inflammation.   None of the ferrets experienced any 
elevated temperature or injection site inflammation following the prime round of vaccination.  
Day 1 following the boost dose, 6/6 ferrets receiving the mock rOMV vaccine and 6/6 ferrets 
receiving the M2e4xHet rOMV vaccine exhibited slight to moderate inflammation, as indicated 
by redness and swelling at the injection site.  By day 3 post boost dose, the injection sites had 
recovered to normal in 6/6 ferrets in the mock rOMV group and 5/6 ferrets in the M2e4xHet 
rOMV group.  None of the ferrets in the Fluvirin group experienced any inflammation.  None of 
the ferrets in any cohort exhibited elevated temperatures, except 1 ferret in the M2e4xHet rOMV 
group.  This one ferret’s body temperature rose from a baseline temperature of 39 °C prior to 
vaccination to 40 °C 1 day post vaccination.   While these side effects are not desirable, all were 
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transient and none caused the ferrets severe distress.  IgG anti-M2e titers were assessed 8 weeks 
post prime vaccination and showed that all M2e4xHet rOMV immunized ferrets developed high 
titers, whereas mock rOMV and Fluvirin immunized ferrets had anti-M2e titers that were 
indistinguishable from pre-vaccination sera (Figure 6a).  Fluvirin is a subunit hemagglutinin 
vaccine and was not expected to elicit anti-M2e titers.  Ferrets were challenged with pandemic 
A/California/7/2009 virus (pdmH1N1) 9 weeks post initial vaccination and their body 
temperature and weight monitored.  Day three post challenge, 3 ferrets from each group were 
euthanized and lungs removed to assess viral titers.   Ferrets vaccinated with M2e4xHet rOMVs 
showed a significant (p<0.01) 2-log reduction in lung viral titer compared to ferrets vaccinated 
with mock rOMVs (Figure 6b). Nasal turbinates and tracheas were also excised and assessed for 
lung viral titers, but neither the M2e4xHet nor Fluvirin vaccinated mice had titers that were 
significantly reduced from mock rOMV vaccinated mice (Figure S4a). Ferrets in the Fluvirin 
group lost less weight than ferrets in the mock rOMV group and M2e4xHet rOMV groups, but 
the difference was not significant (Figure S4b). None of the groups of ferrets showed significant 
changes in temperature (Figure S4c).  Overall, the mild side effects, high antibody titers, and 
low viral lung titers that resulted from M2e4xHet rOMV ferret immunization provide further 
evidence that CC rOMVs are a viable adjuvant platform. 
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Figure 6: (a) Total IgG anti-M2e titers of ferrets 8 weeks post prime vaccination.  
Error bars indicate 95% C.I. of geometric mean (n=6 CC rOMV vaccinated ferrets) 
(* p<0.01).  (b) Lung viral titers of ferrets 3 days post challenge with influenza strain 
pdmH1N1. Lung titers compared using ANOVA followed by comparison to mock 
CC rOMVs using Bonferroni method of correction (n=3). Error bars indicate standard 
deviation of log transformed egg infectious dose (EID50) per gram lung tissue (* 
p<0.01).   
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Discussion 
Lipid IVa containing E. coli strain ClearColi® was successfully engineered through genetic 
knockout to increase rOMV production.  The CC derived rOMVs offer a clear advantage over 
Nsl rOMVs in terms of their safety profile, as indicated by their reduced pyrogenicity in vitro 
and substantial attenuation of negative side effects in vivo.  Although CC was developed to 
simplify the process of producing endotoxin-free proteins, CC rOMVs are still sufficiently 
immunogenic to serve as a potent adjuvant platform. Furthermore, the ability of CC rOMVs to 
adjuvant the immune response is applicable to both peptide-scale antigens, such as M2e4xHet 
(11.5 kDa), and protein-scale antigens, such as GFP (27 kda).  Both constructs led to high IgG 
titers that were equivalent to those generated by GFP in BL21-derived rOMVs.  This work 
highlights the improved safety and versatility of the CC rOMV platform, greatly increasing its 
potential for use in larger animal systems.   
One metric used to assess the safety of the CC rOMV platform was a pyrogenicity 
analysis using human whole blood.  Traditionally, a limulus amebocyte lysate (LAL) assay is 
used to assess endotoxin in samples; however, this assay is not sensitive to the reduced toxicity 
of different lipid A acylation patterns, or to pyrogens other than endotoxin, making it unsuitable 
for assessing CC rOMV-associated toxicity43. The rabbit endotoxicity test is also standard, but 
for these translationally-minded studies it was deemed more clinically relevant to use human 
blood samples in lieu of rabbits.  The United States Pharmacopoeia recommends a maximum 
endotoxin level of 5 EU/kg for most drugs, which is the highest dose of endotoxin that does not 
elicit fever in humans or rabbits; however, vaccines are exempt from this clause44. The EU levels 
associated with specific vaccines are not widely reported, though one paper has extrapolated 
EU/mL levels of vaccines to show that some vaccines exceed this threshold; the typhus vaccine 
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has about 800 EU/kg and the typhoid vaccine has 8000 EU/kg45.  The BALB/c mice weighed 
approximately 20 g when given their prime vaccination, which, given the data in Figure 2a, 
corresponds to ~600 EU/kg, or of 120 EU/mL for a 40 µg CC rOMV dose. Thus, though the 
vaccines do contain significantly more endotoxin than allowable for a traditional drug, they are 
lower than several vaccines currently used in humans. Future testing will identify the minimal 
CC rOMV dose needed to elicit a protective effect in murine models, as well as other relevant 
animal models of infectious disease.    
The TLR agonist analysis indicated that CC rOMVs strongly stimulated TLR2, 
suggesting that it is critical to the immunogenicity of CC rOMVs.  Additionally, the TLR4 data 
highlighted that CC rOMVs stimulate murine TLR4, but not human TLR4.  While this ability of 
CC rOMVs to stimulate mTLR4 indicates that the mouse studies should be interpreted with some 
caution, the lack of weight loss following vaccination with CC rOMVS indicates that the TLR4 
agonism is significantly reduced compared to that caused by the wild type LPS in Nsl. Follow up 
studies using a humanized TLR4 mouse model could perhaps better ascertain the impact of 
TLR4 signaling on the immune response to CC rOMVs, though the current humanized TLR4 
mouse model is on the Th1 biased C57BL/6 background46. Further work using murine TLR2, 
TLR4, and TLR2/4 knockout models will help to better define the mechanisms of adjuvant 
activity by CC rOMVs.  Also interesting was that neither NOD1 nor NOD2, which both detect 
PAMPS located in peptidoglycan, were stimulated by CC rOMVs. Thus, though rOMVs derived 
from some pathogens, such as H. pylori, strongly stimulate NOD1, none of the E. coli derived 
rOMVs tested relied on NOD signaling to generate a response47.   Overall, CC rOMVS appear to 
stimulate primarily through TLR2 stimulation, though future work can help to address other—
and perhaps synergistic—signaling that may be occurring.   
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BALB/c, C57BL/6, and DBA/2J mice generated high IgG titers when vaccinated with 
CC rOMVs.  That BALB/c mice vaccinated with CC rOMVs developed equivalent total IgG 
anti-M2e titers to Nsl rOMV vaccinated mice is somewhat surprising, given the attenuated 
mTLR4 signaling and lack of TLR5 signaling from the CC rOMVs.  However, previous work 
has demonstrated that TLR2 stimulation alone is sufficient to drive high anti-M2e titers in 
mice48. Additionally, the in vitro DC work reported here demonstrated that similar levels of 
mature DCs are produced following CC or Nsl rOMV stimulation.  Thus, though CC rOMVs 
contain a slightly less diverse PRR profile than Nsl rOMVs, they still are effective at generating 
high IgG titers.   
All BALB/c and C57BL/6 CC rOMV immunized mice survived PR8 challenge, though 
the C57BL/6 mice experienced greater weight loss than the BALB/c vaccinated mice after 
exposure to PR8.  While the IgG2c titers developed by C57BL/6 mice were equivalent to the 
IgG2a titers developed by BALB/c mice, C57BL/6 mice had significantly lower IgG1 titers. It is 
possible that the higher dose of influenza required for the C57BL/6 mice affected the response, 
or that there was a difference in T cell response. Wolf et al. produced multi-antigenic peptide 
influenza vaccines comprised of four M2e peptides and two T helper cell epitopes adjuvanted 
with either CpG DNA or cholera toxin that elicited a robust antibody response in BALB/c mice, 
but not C57BL/6 mice, which they attributed to a lack of T cell responsiveness49.  While some 
controversy remains, C57BL/6 mice should be capable of generating potent anti-M2e antibodies; 
Rosendahl Huber et al. demonstrated the capability of C57BL/6 mice to develop weak titers 
against M2e when vaccinated using a M2e-based peptide vaccine adjuvanted with incomplete 
Freund’s adjuvant and CpG DNA, though there was no difference in weight loss between 
vaccinated and non-vaccinated mice when challenged with influenza A virus X3150. Lee et al. 
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found that M2e VLP particles supplemented with AS04 were sufficient to elicit protection in 
C57BL/6 mice against PR8 challenge, but that supplementation with monophosphoryl lipid A 
(MPL) or alum was not sufficient51.  Using the CC rOMV vaccine, protection against PR8 
influenza challenge in BALB/c and C57BL/6 mice and X-47 influenza challenge in DBA/2J 
mice was elicited without addition of any supplemental adjuvants (i.e. alum, CpG DNA). X-47 is 
a reassortant virus comprised of the hemagglutinin and neuraminidase from A/Victoria/3/1975 
and all other proteins from PR8; thus, the M2 protein is the same in both X-47 and PR8 virions, 
making it unsurprising that the CC M2e4xHet rOMV vaccine was effective against both X-47 
and PR852.  Future work will further investigate the ability of CC M2e4xHet rOMVs to protect 
against influenza A strains with more divergent M2e peptides.  Overall, the ability of CC rOMVs 
to protect mice of different genetic backgrounds from different influenza subtypes highlights the 
robustness of the CC rOMV adjuvant platform. 
The ferret study further demonstrates that CC rOMVs remain immunogenic, even when 
used in a different animal model. Though the ferret model is frequently used for influenza 
vaccine trials, no literature to our knowledge has yet examined the interaction of lipid IVa with 
ferret TLR4, making it difficult to determine the degree to which TLR4 signaling is playing a 
role in the immune response to CC rOMVs. The literature further emphasizes the variability of 
lipid IVa signaling by species—it is a weak agonist of equine TLR4, but an antagonist in canine 
TLR453.  Further studies into the response of ferrets to lipid IVa will help us to better evaluate 
the immunogenicity of CC rOMVs in humans.  
The ferrets that received the CC M2e4xHet rOMVs had statistically significant reduced 
viral lung titers compared to CC mock rOMVs, while ferrets the received Fluvirin had reduced—
but not statistically significantly reduced—viral lung titers compared to CC mock rOMVs.  This 
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result is of especial interest because one of the three HA variants that Fluvirin contains, derived 
from virus A/Christchurch/16/2010, is extremely similar to the HA in pdmH1N1, and leads to 
neutralizing antibodies being formed that are effective against pdmH1N154.  Thus, the M2e4xHet 
CC rOMV vaccine did a better job at controlling influenza infection at day three post challenge 
than the FDA approved Fluvirin vaccine designed to generate neutralizing titers against the 
challenge pdmH1N1 virus.  While the ferrets that received CC rOMVs had reduced viral lung 
titers, they did exhibit weight loss in response to influenza challenge.  Because antibodies against 
M2e are believed to drive protection through antibody dependent cellular cytotoxity, not viral 
neutralization, as Fluvirin does, some weight loss is unsurprising33,55.  Further work challenging 
ferrets with different flu subtypes will provide a better assessment of CC-rOMVs as a pandemic 
influenza vaccine.  Additionally, a dosing study is necessary to determine the optimal CC 
M2e4xHet rOMV dose size for the ferrets.  In another recent study involving an M2e-VLP 
platform, Music et al. found no difference in weight loss or in nasal viral titers between M2e-
VLP vaccinated ferrets and naïve ferrets; however, they did not check the viral titers of the lungs, 
precluding a direct comparison to our results56.  Interestingly, when Music et al. then 
supplemented their M2e-VLPs with a seasonal flu vaccine, this combination led to a reduction in 
both weight loss and viral titers following challenge.  Thus, future work could examine the 
possibility of combining M2e CC-rOMVs with other influenza vaccines. Overall, the reduction 
of viral lung titers in CC rOMV vaccinated ferrets indicates that the CC-rOMVs warrant further 
investigation as an influenza vaccine platform.   
CC rOMVs represent a viable new adjuvant platform that offers benefits to current 
rOMV platforms. CC rOMVs retain the positive aspects of the rOMV vaccine platform—simple 
to produce, inexpensive, highly pathogen mimetic—but contain only the lipid IVa portion of 
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LPS, giving them significantly greater translational potential than other available rOMV 
platforms.  Even without a strong Th1 bias, CC rOMVs still elicit a robust humoral response.  
Furthermore, vaccination with CC M2e4xHet-rOMVs garnered complete protection to mice in a 
lethal influenza challenge against mouse strains with different MHC haplotypes and reduced 
lung viral titers in ferrets challenged with human pdmH1N1 influenza. While CC rOMVs 
certainly hold promise in influenza vaccine development, this versatile platform has the potential 
for use in vaccines against a range of pathogens, and offers a viable alternative to alum-based 
adjuvants.   
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CHPATER 4 
SINGLE DOSE, PLGA ENCAPSULATED M2E RECOMBINANT OUTER MEMBRANE 
VESICLE VACCINE ELICITS ROBUST, LONG-TERM PROTECTION AGAINST 
INFLUENZA A VIRUS IN BALB/C MICE 
 
Introduction 
Single dose vaccines offer numerous benefits over a traditional vaccine regimen, which typically 
requires a prime dose followed by one or more boost doses.  Vaccines that require just a single 
dose for efficacy have the potential to increase vaccine coverage, reduce costs, and save time, as 
patients would require only one healthcare visit1.  Additionally, in a pandemic setting, it is 
desirable to generate a protective response as rapidly as possible, yet many inactivated vaccines 
require a boost dose to be protective.   Thus, there is great interest in development of a 
controlled-release vaccine formulation that elicits rapid and long lasting protection.   
 Poly(lactic-co-glycolide) (PLGA), a Food and Drug Administration (FDA) approved 
biodegradable polymer, has been employed numerous times for drug delivery applications, as is 
extensively reviewed2–4.  Through use of emulsion techniques, PLGA microparticles (µP) can be 
used to encapsulate and slowly release peptides and proteins, which has resulted in many FDA 
approved products5,6.  Controlled release vaccine formulations using PLGA µP to encapsulate 
subunit proteins and adjuvants have demonstrated moderate degrees of success, though none are 
yet commercially available7. In addition to providing a tunable method for controlling antigen 
release, PLGA µP can be formulated into sizes that facilitate their uptake by macrophages and 
dendritic cells, both of which are professional antigen presenting cells8,9.  While PLGA µP have 
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been studied for use in protein subunit—and even DNA—vaccine delivery systems, significantly 
less work has investigated their ability to release liposomes, or other small vesicles10.   
Recently, E. coli derived recombinant outer membrane vesicles (rOMVs) demonstrated 
potential as a safe and effective vaccine platform that directly couples adjuvant with antigen11,12.  
Transformation of hypervesiculating strains of E. coli with a plasmid that contains a 
transmembrane protein, cytolysin A (ClyA) followed by an antigen of interest, results in the 
shedding of outer membrane vesicles (diameter: 50-200 nm) that display the antigen of interest 
on their surface13,14.  These rOMVs can then be collected, suspended in phosphate buffered 
saline (PBS), and used as a vaccine, without need for further protein purification or addition of 
supplemental adjuvants. In particular, rOMVs displaying the antigen M2e4xHet, derived from 
the highly conserved matrix 2 protein ectodomain, have demonstrated the ability to protect 
against different influenza A subtypes, making M2e4xHet rOMVs a candidate for a pandemic 
influenza A vaccine11.  Thus, using M2e4xHet rOMVs, we sought to (1.) determine the 
feasibility of encapsulating rOMVs in PLGA µP (2.) create a single dose vaccine that would 
elicit equivalent protection to a typical prime/boost rOMV regimen, and (3.) assess the longevity 
of a single dose rOMV formulation vs. typical prime/boost regimen.      
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Materials and Methods 
M2e-rOMV generation and characterization 
Recombinant OMVs were prepared as previously described11,15. Briefly, E. coli strain ClearColi® 
ΔnlpI (CC) was transformed with a pBAD plasmid containing transmembrane protein cytolysin 
A (ClyA) followed by an antigen (M2e4xHet) derived from the ectodomain of the matrix 2 
protein (M2e) of influenza A virus.  M2e4xHet has previously been expressed on rOMVs and is 
comprised of four M2e variants separated by glycine-serine linkers and ending in a His-tag11.  
Bacteria were inoculated in terrific broth (TB) (ThermoFisher Scientific, Waltham, U.S.), grown 
overnight, then sub-cultured to OD600 = 0.08.  When bacteria reached mid-log phase growth, 
ClyA-M2e production was induced by addition of L-arabinose to a final concentration of 0.2%.  
18 h post induction, bacteria were centrifuged (5000 rcf, 10 min, 4° C) and supernatant passed 
through a 0.2 µm filter. Filtrate was further centrifuged (130,000 rcf, 3 h, 4° C), then supernatant 
decanted and remaining rOMV pellet suspended in sterile phosphate buffered saline (PBS), 
aliquoted, and stored at -20° C until use.  Total protein concentration in rOMV samples was 
measured using a Pierce BCA Protein Assay kit according to the manufacturer’s instructions 
(ThermoFisher Scientific, Waltham, U.S.).  M2e4xHet content was assessed via Western Blot 
using an anti-His6x primary antibody (Sigma-Aldrich, St. Louis, U.S.).  
 
Synthesis of M2e4xHet rOMV loaded PLGA microparticles  
Microparticles loaded with rOMVs were formulated via a water-in-oil-in-water double emulsion 
(w/o/w). 250 mg of poly(lactic-co-glycolide) (PLGA) (38-54 kD) with a 50:50 ratio of lactide to 
glycolide ratio (Sigma-Aldrich, St. Louis, U.S.) was dissolved in 4 mL of dichloromethane 
(DCM) (VWR, Radnor, U.S.) . A water-in-oil (w/o) emulsion was then prepared by adding 400 
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µL of rOMVs at a concentration of 20 mg/mL dropwise to the surface of DCM/PLGA solution.  
Emulsification was produced by homogenization at 26,000 rpm with a small sawtooth dispersion 
head for 30s. The resulting solution was added drop-wise into 60 mL of a 1.3% polyvinylalcohol 
(PVA) (31-50 kD) (Sigma-Aldrich, St. Louis, U.S.) solution and homogenized for 5 min with a 
large dispersion head at a speed of 3000 rpm to form the double emulsion (w/o/w). The PVA-
PLGA-rOMV solution was then poured into 200 mL of a 0.3% PVA solution. The solution was 
stirred uncovered in a fume hood for 7 h to facilitate DCM evaporation. Subsequently, PLGA 
micrparticles were washed 3x by centrifugation (4000 rcf, 4° C, 10 min) followed by 
resuspension in 40 mL of sterile water.  After the third wash, microparticles were resuspended in 
13 mL of sterile water, aliquoted, lyophilized, then stored at -20° C until use.   
 
Characterization of protein loading of PLGA microparticles  
PLGA µP were sputter coated with Au/Pd, then imaged on a Tescan MIRA3 scanning electron 
microscope (SEM). Total encapsulated rOMV protein was determined by dissolving a known 
mass of rOMV loaded PLGA microparticles (µP) in 0.5mL of 0.1M NaOH containing 0.5% 
sodium dodecyl sulfate (SDS) (Sigma-Aldrich, St. Louis, U.S.) and incubating under continuous 
rotation at 37°C for 24hr (n=4 samples). The solution was then neutralized with 0.5mL 0.1M 
HCl in PBS and protein concentration of released rOMVs measured using a Pierce BCA Protein 
Assay (ThermoFisher Scientific, Waltham, U.S.). Total encapsulated rOMV protein was divided 
by mass of PLGA µP to determine percent protein encapsulation.  Encapsulation efficiency was 
calculated as percent µP encapsulated protein out of total protein added during µP formulation.   
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In vitro release profile of rOMV-loaded PLGA microparticles  
In vitro release profiles were generated by suspending particles in 0.5 mL of PBS and incubating 
at 37℃ under continuous rotation (n=4 samples). Every other day for 30 days and then once 
weekly, particles in solutions were centrifuged (5000 rcf, 20° C, 5 min), then 250 µL of 
supernatant was collected and replaced by an equal volume of PBS. Protein concentration was 
quantified using the FluoroProfile Protein Quantification Kit (Sigma-Aldrich, St. Louis, U.S.).  
Assay was stopped upon microparticle degradation and adsorption to tube, as well as 
stabilization of protein release (Day 51).  
 
Mouse immunization and study design 
Three groups (n=15 per group) of seven-week-old female BALB/c mice (Jackson Laboratories, 
Bar Harbor, U.S.) were immunized subcutaneously (s.c.) with 200 µL of the appropriate vaccine. 
The 3 vaccine regimens were as follows: (1) a single dose of PLGA microparticles loaded with 
40 µg of M2e4xHet rOMVs suspended in a PBS solution that contained an additional 40 µg of 
non-encapsulated (free) M2e4xHet rOMVs (group PLGA µP), (2) a prime dose of 40 µg of free 
M2e4xHet rOMVs in PBS and a boost dose of the same composition 4 weeks later (group free 
rOMVs), (3) a prime (sham) vaccination of PBS followed by a boost does of PBS 4 weeks later 
(group PBS (sham)).  Approximately 5% of total rOMV protein is M2e4xHet, resulting in 40 µg 
of rOMVs containing ~2 µg of M2e4xHet antigen.  Each of these vaccination groups of 15 mice 
was further divided down into 3 cohorts: cohorts 1 and 2 were challenged at 10 weeks post prime 
vaccination, cohort 2 was euthanized 6 days post challenge, and cohort 3 was challenged at 26 
weeks (~6 months) post prime vaccination (Figure 1C). Sub-mandibular blood collection was 
performed at weeks 0, 4, 6, 8, 10, 14, 18, 22, and 26 post prime vaccination. All mouse work was 
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conducted according to protocols approved by Cornell’s Institutional Animal Care and Use 
Committee (IACUC). 
 
M2e enzyme linked immunosorbent assay (ELISA) 
ELISAs to determine anti-M2e IgG, IgG1, and IgG2a titers were performed as previously 
described11.  Briefly, 96 well Nunc Maxisorp plates (Thermofisher Scientific, Waltham, U.S.) 
were coated with M2e peptide (SLLTEVETPIRNEWGCRCNDSSD) (Lifetein, Hillsborough, 
U.S.) at 2 µg/mL in PBS and incubated at 37° C overnight.  Plates were washed 2x using wash 
buffer (PBS with 0.3% bovine serum albumin (BSA) and 0.05% Tween20), then blocked in PBS 
with 5% milk (Biorad) (20° C, 1h).  Plates were washed 3x, then 2-fold serial dilutions of sera 
added (n=3 technical replicates, 1 PBS sham control sera sample included per plate) and 
incubated (37° C, 2 h).  Plates were washed 3x, then incubated with appropriate biotin-
conjugated secondary antibody (IgG, IgG1, IgG2a) (eBiosciences, San Diego, U.S.) (37° C, 1 h). 
Plates were washed 3x, then incubated with avidin-horse radish peroxidase (Sigma-Aldrich, St. 
Louis, U.S.) (37° C, 30 min).  Plates were washed 5x, then developed in the dark with TMB 
(3,3',5,5'-Tetramethylbenzidine) (20° C, 20 min).  Reaction was stopped through addition of 4N 
H2SO4 and absorbance read at OD450 and background absorbance read at OD570.  ELISAs were 
analyzed by first subtracting background OD570 absorbance from OD450 absorbance. Next, the 
average plus 3 standard deviations of the control sera OD was calculated for each dilution.  
These control sera values were subtracted from the vaccinated sera samples and the titer was 
called as the highest dilution that was still positive.     
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Influenza challenge  
Mice were challenged with a lethal dose of mouse-adapted H1N1 influenza strain A/Puerto 
Rico/8/1934 (PR8) (BEI Resources, Manassas, U.S) as previously described11.  Briefly, PR8 
stock was thawed on ice, then diluted to a concentration of 1 fluorescent forming unit (FFU)/ µL 
in sterile PBS.  50 µL of this solution (50 FFU of PR8) was administered intranasally to mice 
under isoflurane anesthesia.  Mice were checked on twice daily and weighed once daily to assess 
response to influenza.  Mice were euthanized if weight dropped more than 30% from original 
weight, or if they displayed signs of severe distress.   
 
Enzyme-linked Immunospot (ELISPOT) assay 
Day 5 post challenge, ELISPOT plates (EMD Millipore, Billerica, U.S.) were coated with anti-
IFNγ or anti-IL-4 (R&D Systems, Minneapolis, U.S.) and placed at 4° C overnight. Day 6 post 
challenge, mice in cohort 2 were euthanized and spleens ascetically removed and placed in 
complete RPMI media (RPMI media, 10% heat inactivated fetal bovine serum (FBS), 50 U/mL 
penicillin, 50 U/mL streptomycin) (Thermofisher Scientific, Waltham, U.S.) on ice.  Spleens 
were subsequently mashed into petri dishes using 10 mL complete RPMI media, then filtered 
through a 70 µm sterile screen.  Splenocytes were centrifuged (500 rcf, 5 min, 4° C), then 
suspended in 1 mL of red blood cell (RBC) lysis buffer (Sigma-Aldrich, St. Louis, U.S.).  One 
minute after addition of RBC lysis buffer, 10 mL of complete RPMI media was added and cells 
spun down (500 rcf, 5 min, 4° C) and washed 2x.  Cells were subsequently diluted to a 
concentration of 1x106 cells/mL. The ELISPOT plates were blocked with complete RPMI media 
for 1h, then 200 µL of splenoctyes were added per well (5 spleens per cohort, with 3 technical 
replicates performed from each spleen for each condition).  Cells were stimulated with M2e 
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peptide (5 µg/mL), PBS, or cell stimulation cocktail (positive control) (eBiosciences, San Diego, 
U.S.).  Plates were incubated at 37° C with 5% CO2 for either 24 h (IFNγ) or 48 h (IL-4).  Plates 
were then washed using wash buffer (as described for ELISA) and incubated with anti-IFN or 
anti-IL-4 (37° C, 1h).  Plates were washed 3x, then incubated with avidin-HRP (37° C, 30 min). 
Plates were washed 3x with wash buffer and 2x with plain PBS, then developed using 3-Amino-
9-ethylcarbazole (AEC) (BD Biosciences, San Jose, U.S.) and monitored in the dark until spots 
appeared, then reaction stopped through addition of tap water.  Plates were dried then sent to 
ZellNet for reading and spot enumeration (ZellNet Consulting, Inc., Fort Lee, U.S.). 
 
Statistics 
ELISAs were analyzed using n=3 technical replicates per sample per mouse.  Titers were 
averaged using a geometric average and graphed with 95% confidence intervals.  IgG titers were 
compared between the PLGA µP and free rOMVs groups by using a Mann-Whitney test.  IgG1: 
IgG2a titers were compared using a Wilcoxon matched-pairs sign test.  Mouse morbidity data 
was compared using a two-way ANOVA followed by Sidak’s test to allow for multiple 
comparisons between the vaccine groups.  Mouse mortality data was analyzed using a log-rank 
test followed by Bonferoni method of correction between groups.  ELISPOT data was analyzed 
by averaging the technical replicates (n=3) for each spleen, then comparing data from the PLGA 
µP vaccinated mice spleens and free rOMVs vaccinated mice spleens to the PBS vaccinated 
mice spleens using an ANOVA followed by using Dunnett’s method to allow for multiple 
comparisons.  Statistics were calculated using Graphpad Prism7 (La Jolla, U.S).   
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Results 
rOMV loaded PLGA microparticles with first order release profile synthesized and 
characterized 
Poly(lactic-co-glycolide) microparitlces (PLGA µP) loaded with M2e-rOMVs were synthesized 
using standard PLGA µP production techniques.  Size of rOMV loaded PLGA µPs was assessed 
using scanning electron microscopy (SEM); µPs were fairly polydispered, with an average 
diameter and standard deviation of 4.22 +/-2.8 µm (Figure 1A).   M2e rOMVs ranged in size 
from ~50-200 nm, indicating that multiple rOMVs could be contained within each PLGA µP11,15.  
Encapsulation efficiency of total rOMVs (measured in total protein content) added to PLGA 
solution to percent protein PLGA polymers encapsulated was 37.6%.  PLGA µP contained 
2.18% rOMVs/ PLGA mass (w/w).  In vitro analysis for rOMV release from PLGA µPs shows a 
first order release profile that stabilized after 40 days (Figure 1B).  Previously, prime and boost 
rOMV vaccinations administered 4 weeks apart resulted in development of high anti-M2e titers 
and subsequent protection from influenza challenge11.  Thus, the degradation time period of 40 
days—which is likely accelerated in vivo—seemed appropriate for delivery of a vaccine dose.   
Overall, the ability of rOMV loaded PLGA microparticles to be formed with a long-term in vitro 
release profile indicated that there was potential for their use as a single dose vaccine.   
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Figure 1: (A) SEM image of M2e4xHet rOMV loaded PLGA 
microparticles. (B) In vitro release profile of M2e4xHet rOMV loaded 
PLGA microparticles in PBS at 37° C (n=4 samples). (C) Experimental 
timeline. 
 
 
PLGA rOMV vaccination leads to high anit-M2e titers 
Rapid production of high IgG titers is useful for the creation of a pandemic vaccine, where it is 
desirable to generate a protective response as quickly as possible.  Mice were given either a 
single dose of PLGA µP containing 40 µg encapsulated rOMVs and 40 µg free rOMVs in PBS 
or two doses (a prime and a boost doses separated by four weeks) of 40 µg of free rOMVs 
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(Figure 1C).  An additional control group of mice received only phosphate buffered saline 
(PBS) in their vaccines.  Blood was collected from the mice every 2-4 weeks to assess the 
humoral response to the vaccine.  Mice vaccinated with free rOMVs generated an anti-M2e 
geometric mean titer of 1,800 4 weeks post prime dose, whereas mice vaccinated with rOMV 
loaded PLGA µPs had a geometric mean titer of 53,200 (Figure 2A).   By 6 weeks post prime 
vaccination (and 2 weeks post boost vaccination of the free rOMVs group) there was no 
significant difference in anti-M2e IgG levels between the PLGA µP vaccinated group and the 
free rOMVs group.  Titers remained high and were statistically equivalent at week 8.  In addition 
to total anti-M2e IgG levels, anti-M2e IgG1 and anti-M2e IgG2a levels were also measured.  
Elevated IgG2a: IgG1 ratios are associated with a Th1 biased immune response, useful for 
clearance of viral infections, such as influenza infection.   At week 4, both IgG1 and IgG2a anti-
M2e titers were barely above those of naïve sera (dotted line) in the free rOMVs group (Figure 
2B).  Mice in the PLGA µP group had high and statistically equivalent levels of both IgG1 and 
IgG2a anti-M2e antibodies.  By week 8, the free rOMVs group of mice also had high and 
statistically equivalent IgG1 and IgG2a anti-2e antibody levels (Figure 2C).  Somewhat 
surprisingly, at week 8, the PLGA µP vaccinated mice had slightly elevated IgG1 titers relative 
to IgG2a (* p<0.05).  Despite this slightly skewed Th2-biased response, the high anti-M2e IgG 
titers indicated that PLGA µP encapsulated rOMVs were still capable of eliciting a robust 
humoral response.  
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Figure 2: (A) Anti-M2e IgG titers elicited by PLGA µP and free 
rOMVs.  (B,C) Anti-M2e IgG1 and IgG2a titers at 4 weeks (B) and 
8 weeks (C) post prime.  Titers display geomean average (n=15 
mice) with 95% confidence intervals (* p < 0.05).   
 
 
PLGA rOMV single dose vaccine protects BALB/c mice in influenza A challenge and elicits 
cellular response 
To assess the ability of a PLGA µP rOMV vaccine to protect mice from influenza challenge, 
mice were exposed to a lethal dose of mouse adapted influenza virus A/Puerto Rico/8/1934 
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(PR8).  PBS vaccinated mice all lost more than 30% of their original body weight, necessitating 
euthanasia.  Both PLGA µP vaccinated mice and free rOMVs vaccinated mice had 100% 
survival following challenge (Figure 3A). There was no significant difference in weight loss 
between mice that received the PLGA µP vaccine and mice that received the free rOMVs 
vaccine (Figure 3B). Thus, the µP PLGA vaccine demonstrated that it was possible to create a 
single dose rOMV vaccine that was as effective as the traditional prime/boost rOMV vaccine.   
On day 6 of the challenge, 5 mice (cohort 2) from each of the vaccine groups were 
euthanized and their spleens excised.  Splenocytes were subsequently cultured in the presence of 
M2e peptide or plain PBS and the IFNγ and IL-4 cytokines produced in response to the 
stimulation analyzed via an ELISPOT assay.  IFNγ is associated with a Th1 biased response, 
whereas IL-4 is associated with a Th2 biased response16.  Splenocytes from both PLGA µP and 
free rOMVs vaccinated mice produced significant levels of IFNγ relative to splenoycytes from 
PBS vaccinated mice when stimulated with M2e peptide (Figure 3C).  Mice vaccinated with 
PLGA µP had especially high levels of IFNγ relative to splenocytes from PBS vaccinated mice, 
indicating the µP were causing a Th1 bias, despite the elevated IgG1: IgG2a anti-M2e antibody 
ratio.   Splenocytes from both PLGA µP and free rOMVs vaccinated mice produced significantly 
more IL-4 than PBS vaccinated mice when stimulated with M2e peptide (Figure 3D).  Unlike in 
IFNγ production, PLGA µP and free rOMVs vaccination resulted in similar amounts IL-4 
production.  The presence of IL-4 as well as IFNγ indicates that the rOMVs generate a fairly 
balanced immune response, which matches the balanced IgG1:IgG2a anti-M2e ratio the free 
rOMVs vaccinated mouse group displayed.  There was no difference in IFNγ or IL-4 production 
between vaccine groups when splenocytes were treated with plain PBS instead of M2e peptide.  
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Overall, the complete protection elicited by the PLGA µP vaccine indicates that it is a feasible 
way to formulate a pandemic influenza A vaccine.   
 
 
Figure 3: (A,B) Mortality (A) and morbidity (B) of mice challenged with influenza A/PR8 at 10 
weeks post prime vaccination (n=5 mice). Error bars represent standard error of the mean.  (C,D) 
Production of cytokines IFNγ (C) and IL-4 (D) 6 days post influenza A/PR8 challenge in PLGA 
µP, free rOMVs, and PBS vaccinated mice (n=5 mice). Error bars represent standard deviation of 
average (* p < 0.05).    
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Long term anti-M2e titers result from both PLGA rOMV encapsulated and free rOMV 
vaccination 
Five mice from each of the vaccine groups were not challenged; instead, their anti-M2e IgG 
levels continued to be monitored every 4 weeks to determine the level of antibody attrition that 
occurred with time (Figure 4A).  At 10 weeks post prime vaccination, both the PLGA µP and 
free rOMVs vaccine groups had statistically equivalent anti-M2e IgG titers.   The titers remained 
statistically equivalent over the next 16 weeks, though the average anti-M2e IgG titer was lower 
in the PLGA µP group than in the free rOMVs group.  At 26 weeks post prime vaccination, both 
the PLGA µP group and free rOMV group had balanced, statistically equivalent anti-M2e IgG1 
and IgG2a antibody titers (Figure 4B).  The geometric average of IgG1 and IgG2a anti-M2e 
titers at 26 weeks was lower than the geometric average of IgG1 and IgG2a anti-M2e titers at 8 
weeks in both the PLGA µP and free rOMVs vaccinated groups; however, the differences were 
not significant.  The maintenance of high anti-M2e IgG titers for 26 weeks post the prime 
vaccination indicates that the PLGA µP and free rOMVs vaccines elicit a long-lasting humoral 
response.   
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Figure 4: (A) Anti-M2e IgG titers from week 10 post prime vaccination to 
week 26. (B) Anti-M2e IgG1 and IgG2a titers at 26 weeks post prime 
vaccination. Error bars represent 95% confidence intervals of geometric mean 
(n=5 mice, except week 26 group PLGA µP n=4). 
 
 
PLGA rOMV vaccine protects BALB/c mice from influenza A challenge 6 months post 
vaccination 
Mice in cohort 3 were challenged with mouse adapted influenza A/PR8 at 26 weeks post their 
prime vaccination.  Just as in the challenge that took place at 10 weeks post prime vaccination, 
mice in the PLGA µP group, free rOMVs group, and PBS (sham) vaccination group all received 
a lethal dose of PR8.  Following challenge, 100% (n=4/4) of PLGA µP vaccinated mice, 100% 
(n=5/5) of free rOMVs vaccinated mice, and 0% (n=0/5) PBS vaccinated mice survived (Figure 
5A).  The number of mice in the PLGA µP cohort was 4 not 5, as one mouse developed a 
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recurring abscess and required euthanasia at week 24 post prime vaccination.   Though both 
PLGA µP vaccinated mice and free rOMVs vaccinated mice survived, the PLGA µP vaccinated 
mice experienced significantly more weight loss than the PLGA µP vaccinated mice on days six 
through ten of challenge (Figure 5B).  The weight loss experienced by the PLGA µP vaccinated 
mice was still significantly less than that experienced by the PBS (sham) vaccinated mice.  
Overall, the ability of the PLGA µP vaccine to still protect mice from challenge 6 months after it 
was administered highlights its potential as a single dose vaccine.  That the free rOMVs showed 
such robust challenge protection is also promising, though that vaccine strategy does require both 
a prime and boost dose to be administered.   
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Figure 5: Mortality (A) and morbidity (B) of mice 
challenged with influenza A/PR8 at 26 weeks post prime 
vaccination (n=5 mice, except PLGA µP n=4).  Error bars 
represent standard error of mean (* p < 0.05). 
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Discussion 
PLGA µP loaded with M2e4xHet rOMVs resulted in effective and long-lasting protection from 
influenza A/PR8 challenge.   While other vaccines have used PLGA µP to encapsulate 
inactivated influenza virus, influenza antigens, and influenza DNA, rOMVs have not previously 
been encapsulated by a PLGA system17–19.  Though PLGA microparticles by themselves have 
been shown to enhance immunogenicity, most PLGA vaccine systems require the encapsulation 
of an adjuvant as well as peptides/proteins to generate an immunogenic response20,21. Because 
rOMVs directly couple adjuvant and antigen, no supplemental adjuvants needed to be added.  
Interestingly, when Singh et al. used PLGA µP to encapsulate inactivated influenza A virus 
(IAV), they found that the encapsulated system was less effective than a non-encapsulated IAV 
vaccine22.  Instead, they determined that the best protection from influenza challenge was 
afforded when just an adjuvant (CpG) loaded PLGA particles were delivered along with IAV, 
first in a prime intramuscular dose, and then boosted in an intranasal dose.  Hiremath et al. also 
developed a PLGA-based influenza vaccine system that encapsulated a cocktail of 4 conserved 
influenza A peptides, M2e virus like particles (VLPs), and adjuvant in PLGA nanoparticles 
(average diameter 260 nm)23.  These nanoparticles were delivered to pigs twice intranasally in a 
prime/boost regimen and resulted in a reduction of symptoms and of viral titers during influenza 
challenge.  Thus, there is some precedent for a M2e-VLP system being encapsulated in PLGA, 
though our system used larger PLGA microparticles and did not require a boost dose for 
efficacy.  
Previous research has also investigated the ability to generate a single-dose influenza 
vaccine based on M2e, though not necessarily through use of PLGA µP24.  Conjugation of a 
short M2e consensus sequence to the papaya mosaic virus was recently used to create a single 
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dose pandemic influenza vaccine.  Following a single dose of this vaccine, 70% of BALB/c mice 
survived lethal influenza challenge and there was as strong positive correlation between IgG2a 
titers and survival25.  While our vaccine did not elicit elevated IgG2a: IgG1 anti-M2e antibody 
titers, there still were significant quantities of IgG2a antibody present, which likely contributed 
to the protective response. 
The rapid development of anti-M2e IgG titers by our PLGA µP vaccine was likely 
enhanced by the presence of free rOMVs in the PLGA µP formulation. Substantial research 
efforts have gone into characterizing the degradation of PLGA microparticles in tissues and 
characterizing the release profiles that results from PLGA microparticles of varying 
compositions and sizes26.  Additionally, other systems have explored the delivery of antigen in a 
controlled release manner that mimics natural infection or a prime/boost dosing regimen27.  
However, our work found that the simple approach of suspending PLGA particles in an rOMV 
solution led to titers that were equivalent to those elicited in prime/boost dosing.  Future work 
comparing our PLGA µP formulation to one where the entire prime plus boost dose (80 µg) is 
contained within the PLGA µP will help to better ascertain the benefit that free rOMVs offer in 
the initial priming.   
One major challenge to controlled release vaccines is stabilization of the formulation.  
The PLGA µP vaccine described in this paper, which is suspended in an rOMV solution prior to 
delivery, requires storage at -20° C.  Now that we have established that a single dose controlled 
release vaccine system for rOMVS is feasible, future work will be directed at developing 
formulation strategies to allow storage of the vaccines at warmer temperatures prior to use.  One 
well-known downside to PLGA particles is that they create an acidic environment upon 
degradation, which can denature encapsulated antigens; groups have tried different approaches to 
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mitigate this problem28. Hanson et al. displayed antigens on lipid-enveloped PLGA particles, 
which kept the antigen away from the acidic PLGA core29.  Tzeng et al. incorporated Eudragit® 
E PO into a PLGA microparticle-based inactivated polio virus (IPV) vaccine, which both 
prevented IPV from denaturing and generated a delayed burst release of IPV30.  Because M2e is 
a linear epitope, rOMV denaturation due to the acidic environment that forms as PLGA 
microparticles degrade is less of a concern than it would be for a conformational epitope  
While it is promising that both the PLGA µP and free rOMVs vaccines remained 
protective after 6 months, it is unknown how much longer that protection would be maintained; 
already, the mice in the PLGA µP group showed increased morbidity in the 26 week challenge 
vs. the challenge that took place at 10 weeks.  Previously, a M2e-based influenza vaccine entered 
a Phase I clinical trial, but was hampered by high antibody attrition31.  However, the lifespan of a 
laboratory mouse is only about two years, so the protection at 6 months past prime vaccination 
that our vaccines provided represents a significant portion of a mouse lifespan32.  Some subunit 
vaccines, such as GardasilTM for cervical cancer, produce titers that drop some, but then remain 
stable for yeas, maintaining protection (in humans)33. Further work exploring vaccination of aged 
mice, instead of 7-week-old mice, and use of other animal systems will allow a more nuanced 
view of the longevity of rOMV-based vaccines.  
The splenocytes of PLGA µP and free rOMV vaacccinated mice produced IFNγ and IL-4 
in response to M2e peptide stimulation, indicating a cellular response.  Interestingly, PLGA µP 
vaccinated mice produced significantly more IFNγ in response to M2e peptide stimulation than 
splenocytes from free rOMVs vaccinated mice during the challenge that took place 10 weeks 
post prime vaccination.  Because spleens were only collected after the first challenge, it is 
unknown whether this response was retained following the 26-week challenge.  The PLGA µP 
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vaccinated mice lost more weight following the second challenge than the first, indicating that 
protection had waned somewhat during the time period.  Average anti-M2e IgG titers were also 
lower at the 26-week time point, which could have contributed to the difference in morbidity, 
though the 26-week titers were not statistically different from the 10-week titers.  Previously, it 
has been shown that encapsulating antigens and adjuvants in PLGA can lead to increased cellular 
response, due in part to enhancing antigen presentation through uptake by macrophages and 
dendritic cells34. Rubsamen showed that dendritic cells engulfed an average of three particles 
when they were 8 µm in size and 1 particle when they were 11 µm in size35.  Additionally, other 
researchers have added dendritic cell targeting moieties to their microparticle formulations to try 
and enhance cellular uptake36,37.  Further work with our PLGA µP is needed to determine the 
ideal PLGA µP size for optimizing potent—and long lasting—cellular responses.  
In conclusion, vaccination of BALB/c mice vaccinated with a single dose influenza A 
vaccine, comprised of M2e4xHet rOMVs loaded into PLGA µP and suspended in an M2e4xHet 
rOMV solution (group PLGA µP), resulted in 100% survival following lethal influenza A/PR8 
challenges at 10 weeks and 26 weeks post prime vaccination.  The protective response is likely 
to due to both cellular and humoral contributions; following the 10-week challenge, splenocytes 
from both the PLGA µP vaccinated mice and free rOMVs vaccinated mice responded strongly to 
the M2e peptide, producing IFNγ and IL-4 in response.  Additionally, while the average anti-
M2e IgG titers decreased from 10 weeks to 26 weeks post prime vaccination, the difference was 
not significant.  Overall, the PLGA µP represent a simple way to generate single dose rOMV 
vaccines. 
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CHAPTER 5 
DEVELOPMENT OF E. COLI NISSLE DERIVED RECOMBINANT OUTER MEMBRANE 
VESICLES CONTAINING TETRA-ACYLATED AND PENT-ACYLATED 
LIPOPOLYSACCHARIDES FOR USE AS AN INFLUENZA ADJUVANT PLATFORM 
Introduction 
Subunit vaccines often require the addition of an adjuvant to generate sufficient immune 
responses.  Increased understanding of the innate immune system has led to the development of 
adjuvants that target pathogen recognition receptors (PRRs) in the innate immune system, 
allowing for a more tailored immune response1.  One approach to adjuvant design is ‘bottom up’, 
and focuses on the exploration of how different combinations of specific PRRs can generate 
specific immune responses.  An alternative approach to adjuvant design is ‘top down’ and uses 
complex, pathogen-mimetic particles to generate an immune response.  Recently, E. coli derived 
recombinant outer membrane vesicles (rOMVs) have demonstrated potential as a potent adjuvant 
platform for subunit antigen delivery2.  Because rOMVs are derived from a bacterial membrane, 
they naturally contain many pathogen associated molecular patterns (PAMPs), making them a 
complex, but efficacious, adjuvant system3–6.   
 While the pathogen-mimetic nature of rOMVs can help to generate a robust immune 
response, the high lipopolysaccharide (LPS, or endotoxin) content in bacterial outer membranes 
can lead to injection site inflammation and post vaccination scarring.  A strain of bacteria, 
Clearcoli® (CC), whose LPS synthesis pathway was engineered to create a cell membrane 
containing an LPS precursor lipid, lipid IVa, was recently engineered to assist the production of 
endotoxin-free recombinant proteins7.  Previously, we have reported the further engineering of 
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CC to produce rOMVs. These CC rOMVs generated antibody titers against an antigen displayed 
on their surface equivalent to rOMVs derived from a probiotic strain of E. coli, Nissle 1917, 
despite the CC rOMVs lacking full LPS.  Additionally, mice immunized with CC rOMVs 
displaying an influenza A virus derived antigen, M2e4xHet, were 100% protected from a lethal 
influenza challenge.  While CC rOMVs appear to be a highly effective and safe adjuvant 
platform, they elicit a balanced IgG2a:IgG1 antibody ratio against displayed antigens, whereas 
rOMVs derived from Nissle 1917 elicit elevated IgG2a:IgG1 antibody ratios.  IgG2a antibodies 
are desirable for two reasons.  First as a means to neutralize a pathogen, and second to facilitate 
antibody mediated cellular cytotoxicity or antibody mediated phagocytosis8–10. Unlike Clearcoli® 
and other lab strains of bacteria, Nissle 1917 contains flagellin (in its flagella and fimbriae), a 
known TLR5 agonist, which may contribute to the observed Th1 biased immune response11.  
Therefore, we sought to engineer the LPS of E. coli Nissle 1917 to create a less pyrogenic rOMV 
but maintain the desired Th1 biased immune response.  
 There is precedence for engineering E. coli strains to produce OMVs with reduced 
toxicity12.  LPS, also known as endotoxin, stimulates primarily through toll like receptor 4 
(TLR4)13.  While full LPS contains an O-antigen, inner and outer core, and lipid A region, only 
the lipid A portion contributes to TLR4 signaling13,14.  The acyl chains of the lipid A region 
interact with MD-2 and TLR4, facilitating dimerization and signal transduction.   Knock out of 
gene lpxM results in production of pent-acylated LPS, rather than the normal hex-acylated LPS, 
and has been used to reduce toxicity associated with rOMVs15.  However, no work has yet used 
tetra-acylated LPS to produce rOMVs.  While CC rOMVs do contain tetra-acylated lipid A, they 
do not contain complete LPS; they have only lipid IVa, no core region or O-antigen.  Here, 
modified Nissle 1917 E. coli that contains pent-acylated or tetra-acylated LPS was generated 
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through a series of gene knock outs, similar to the approached used to generate CC from parent 
strain BL21(DE3). Unlike CC, no mutation was introduced into Nissle 1917 to remove the 
3‑deoxy-α-D-manno-octulosonic acid (KDO) portion of LPS.  The modified Nissle 1917 strains 
were subsequently transformed with a plasmid containing an influenza antigen, M2e4xHet, and 
used to generate M2e4xHet rOMVs.  These modified-LPS rOMVs were then compared to CC 
rOMVs and wild type Nissle rOMVs to better elucidate the impact of E. coli strain and LPS 
acylation on rOMV adjuvant potential.   
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Materials and Methods 
P1 phage carrying gene knockouts created using Keio collection 
P1 phage carrying DNA from Keio collection, which contain genes knocked out and replaced 
with kanamycin resistance (kanR) genes, were generated as previously described16.  Briefly, E. 
coli strains from the Keio collection containing the desired knockout (lpxT, eptA, crcA, lpxM, 
lpxL, or lpxP) were grown in LB overnight, then subcultured 1:100 into 2 mL LB with 5 mM 
CaCl2, 10 mL MgSO4, and 0.2% glucose for 1.5 h (Sigma-Aldrich, St. Louis, U.S).  
Subsequently, 50 µL of P1 phage was added and culture was grown until no longer turbid, 
indicating successful bacterial lysis (~4 h). Chloroform (10 µL) was added to the culture, the 
culture vortexed, then centrifuged (5 min, 12k rcf).  The supernatant (phage lysate) was collected 
and stored at 4° C until needed.  
 
Gene knockout in Nissle 1917 performed using P1 phage transduction 
E. coli Nissle 1917 knock outs were generated as previously described4.  Briefly, the strain to be 
modified was grown overnight, then 600 µL centrifuged and resuspended in 100 µL of Luria-
Bertani (LB) broth (Thermo Fisher Scientific, Waltham, U.S.) (supplemented with 5 mM CaCl2, 
10 mM SO4, and 0.2% glucose (Sigma-Aldrich, St. Louis, U.S.)) and 100 µL of phage lysate 
(containing the desired gene knock out).  The culture was incubated (37° C, 2 h, 200 rpm), then 1 
mL of LB and 100 µL of 1 M sodium citrate added to the tube and incubation continued for 
another hour.  The culture was then centrifuged (12k rcf, 1 min), resuspended in 100 µL LB 
(with 100 mM sodium citrate), and plated on kan+ (50 µg/mL) sodium citrate+ (100 mM) Petri 
dishes (Corning, Corning, U.S.). Colonies were selected and streaked on kan+, sodium citrate+ 
plates.  Colonies were then grown in LB overnight and sequenced to confirm replacement of 
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desired gene with kanR gene.   
 
Kanamycin resistance genes removed using plasmid pCP20 
Removal of the kanR resistance gene was facilitated through the use of plasmid pCP20.  pCP20 
contains a temperature sensitive origin of replication and contains genes for ampicillin resistance 
and FLP recombinase.  Expression of FLP recombinase excises genes between FRT sites (which 
frame the kanR gene)17.  Briefly, E. coli Nissle strains containing the desired knock out were 
transformed with pCP20, then grown at 30° C overnight on amp+ plates (50 µg/mL). 
Subsequently, colonies were selected, streaked on amp+ plates (50 µg/mL), and grown overnight 
at 30° C.  Colonies were then selected, streaked on antibiotic-free plates, and grown at 42° C 
overnight.  Colonies were selected and each colony streak on a amp+ plate, kan+ plate, and 
antibiotic-free plate, then grown overnight at 37° C.  Colonies that grew on the antibiotic free 
plate, but not the other two plates, were sequenced to confirm removal of kanR gene and that the 
bacterial strain was correct. 
 
Polymerase Chain Reaction (PCR) of Nissle strains confirms gene knock out 
Polymerase chain reaction (PCR) was performed using Phusion polymerase (New England 
BioLabs, Ipswich, U.S.) according to manufacture’s instructions for a 50 µL reaction.  Primers 
used to verify gene knock out are same as used previously to create Clearcoli7. Gene focA was 
sequenced to verify that the strain being modified was Nissle 191718.  Genomic DNA was 
collected for sequencing using a simple boiling method.  Briefly, strains were grown overnight in 
LB.  100 µL of sample was centrifuged (13.1k rcf, 1 min), supernatant removed, and pellet 
resuspend in nuclease free water.  The sample was boiled for 10 min, centrifuged (13.1k rcf, 
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1min), then 2 µL of supernatant added per 50 µL PCR reaction.   
 
Engineering and production of penta-acylated and tetra-acylated Nissle 1917 rOMVs 
Starting with E. coli Nissle 1917 ΔnpI (Nsl-wt), sequential gene knock out was used to produce 
penta-acylated (Nsl-5) and tetra-acylated (Nsl-4) strains. First, genes lpxT (encodes lipid A 1-
diphosphate synthase), eptA (encodes phosphoethanolaminetransferase A), and crcA (encodes 
palmitoyl transferase for lipid A) were knocked out to create Nissle with a more uniform LPS 
composition.  Pent-acylated Nissle (Nsl-5) was then created through knock out of lpxM (encodes 
lipid A biosynthesis myristoyltransferase).  Tetra-acylated LPS was created by further knock out 
of lpxL (encodes lipid A biosynthesis lauroyltransferase) and lpxP (encodes lipid A biosynthesis 
palmitoleoyltransferase). Engineered strains were then transformed with a pBAD plasmid 
encoding a transmembrane protein, ClyA, followed by an influenza antigen, M2e4xHet, and 
grown up to produce rOMVs, as previously described2.  Total surface protein in rOMVs was 
measured using a Pierce bicinchoninic acid (BCA) assay, performed according to manufacturer’s 
instructions (Thermo Fisher Scientific, Waltham, U.S.).  Presence of M2e4xHet antigen was 
confirmed via Western Blot with anti-His antibody (Sigma-Aldrich, St. Louis, U.S.).   
 
Mouse immunization and challenge 
Four cohorts of 7-week-old BALB/c mice (n=5) were subcutaneously vaccinated with either 40 
µg of M2e4xHet CC rOMVs in PBS, 40 µg of M2e4xHet Nsl-4 rOMVs in PBS, 40 µg of 
M2e4xHet Nsl-5 rOMVs in PBS, or PBS. Following vaccination, mice were weighed daily for a 
week to assess the health impact of vaccination.  All mice received a boost dose of the same 
composition of the prime dose 4 weeks post prime vaccination.  At 10 weeks post prime 
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vaccination, mice were challenged with a lethal dose (50 FFU) of influenza A virus A/Puerto 
Rico/8/1934 (H1N1) (PR8) (BEI Resources, Manassas, U.S.) as previously described2.  Briefly, 
mice were lightly anesthetized with isoflurane, then a 50 µL dose of PR8 (1 FFU/mL in PBS) 
delivered intranasally.  Mice were monitored twice daily and weighed once daily to assess their 
response to the influenza challenge.  Mice that lost more than 30% of their original weight, or 
exhibited signs up severe distress, were euthanized.   
 
Toll like receptor (TLR) stimulation studies 
TLR studies were carried out as previously described2.  Briefly, HEK-Blue TLR5-KD cells 
(InvivoGen, San Diego, CA) were plated at 0.15x106 cells/mL in 96 well plates (100 µL/well) 
and grown overnight.  Subsequently, cells were transfected with 5xNF-kβ-luciferase reporter 
plasmid and TLR4/MD-2/CD14, mTLR4/MD-2/CD14, TLR2, or mTLR2 and grown for 28h. 
Cells were then incubated with rOMVs (100 ng/mL), LPS (100 ng/mL), or Pam3Cys (100 
ng/mL) for 16, followed by removal of media and cell lysis to free luciferase.  Luciferase activity 
was measured via addition of 100 µL D-luciferin substrate to 20 µL of lysate and resulting 
luminescence read using a Veritas luminometer (Promega, Madison, WI). 
 
Macrophage stimulation studies 
Macrophages (TLR2 KO, TLR4 KO, and TLR2/4 KO) were plated at 2x105 cells/well (500 µL 
per well) in 24 well plates (Corning, Corning, U.S.) in complete DMEM media (DMEM with 
10% low endotoxin fetal bovine serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-
glutamine, 50 U/mL penicillin, and 50 U/mL streptomycin).  Cells were then stimulated with 
rOMVs (1 µg/mL), LPS (100 ng/mL), or Pam3Cys (1 µg/mL) and incubated for 6h (37° C, 5% 
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CO2, 6h).  Subsequently, media was collected and analyzed for TNF-α via ELISA assay run 
according to manufacturer’s instructions (Biolegend, San Diego, U.S.).      
  
Whole blood pyrogenicity testing 
Whole blood pyrogen test was performed as previously described19.  Blood from healthy human 
donors was collected into heparinized tubes and rotated at room temperature (<2h) until use.  96 
well plates were filled with 200 µL endotoxin free saline and either 20 µL of rOMVs 
(concentrations ranged from 10 µg/mL to 0.001 pg/mL) or 20 µL of endotoxin standards 
(concentration ranged from 10 EU/mL to 0.125 EU/mL), or 20 µL phosphate buffered saline 
(PBS). 20 µL of blood was added per well, then plates incubated (37° C, 5% CO2, 18h).  
Following incubation, plates were centrifuged (500 rcf, 5 min, RT) and supernatants collected 
and used to perform an IL-1β ELISA according to manufacturer’s instructions (Biolegend, San 
Diego, U.S.). 
 
Enzyme-linked immunosorbent assay (ELISA) 
M2e ELISA was performed as previously described2.  Briefly, plates were coated with 2 µg/mL 
M2e1xCys peptide (SLLTEVETPIRNEWGSRSNDSSD) (LifeTein, Somerset, U.S.), 12h, 37° 
C) in PBS overnight.  Plates were blocked, incubated with 2-fold serial dilutions of sera samples 
(2h, 37° C), incubated with biotinylated anit-IgG1, anti-IgG2a, or anti-IgG antibodies (1h, 37° C) 
(eBiosciences, San Diego, U.S.), incubated with avidin-HRP (30 min, 37° C) (Sigma-Aldrich, St. 
Louis, U.S.), then developed with 3,3,5,5-tetramethylbenzidine (TMB) (Thermo Fisher 
Scientific, Waltham) (20 min, 20° C).  Plates were washed 3+ times with PBS-T (0.3% bovine 
serum albumin (BSA), 0.05% Tween20 (Sigma-Aldrich, St. Louis, U.S.)) between each step.   
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Statistics 
Pyrogenicity data was analyzed using a Kruskal-Wallis test followed by comparisons to CC 
rOVMs using Dunn’s test to account for multiple comparisons.  TLR and macrophage data was 
compared using an ANOVA followed by comparisons to PBS using Dunnett’s test to account for 
multiple comparisons.  Weight loss data post vaccination was compared using a 2-way ANOVA 
followed by Dunnett’s test to account for multiple comparisons to PBS.  Mortality data post 
influenza challenge was compared using a log-rank test, followed by using the Bonferroni 
method to account for multiple comparisons to PBS. Weight loss data post influenza challenge 
was compared using a 2-way ANOVA followed by Dunnett’s test to account for multiple 
comparisons to CC rOMVs.   
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Results 
Tetra-cylated and Penta-acylated rOMVs have low pyrogenicity 
Pyrogenicity of CC, Nsl-4, Nsl-5, and Nsl-wt rOMVs was assessed using a whole blood 
monocyte activation pyrogenicity test.  In this test, IL-1β production by monocytes in response 
to rOMVs was correlated to IL-1β production by monocytes in response to known amounts of 
endotoxin.  CC, Nsl-4, and Nsl-5 rOMVs all had statistically equivalent pyrogenicity that was 
approximately 5 log fold lower than that of Nsl-wt rOMVs (Figure 1A).  The significantly lower 
pyrogenicity that Nsl-4 and Nsl-5 rOMVs have relative to Nsl-wt rOMVs suggests that they 
would make a safer vaccine option than Nsl-wt, with less inflammation following injection.   
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Figure 1: (A) Pyrogenicity of a 40 µg dose of rOMVs (* p<0.05). Error bars represent geomean 
average with 95% confidence intervals.  Groups compared using Kruskal-Wallis test followed by 
comparisons to CC rOMVs using Dunn’s test to account for multiple comparisons. (B-E) Cells 
transfected with a NFκβ luciferase reporter and TLR4/MD-2/CD14 (B), mTLR4/mMD-
2/mCD14 (C), TLR2 (D), or mTLR2 (E) were incubated with rOMVs for 16h then measured for 
luciferase production. Error bars represent standard deviation of average.  Groups compared 
using ANOVA followed by comparisons to PBS using Dunnett’s test to account for multiple 
comparisons (* p<0.05, *** p<0.001).   
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Nissle LPS modifications impact TLR signaling 
CC, Nsl-4, Nsl-5, and Nsl-wt rOMVs were incubated with cells transfected with individual TLRs 
to provide an enhanced understanding of rOMV signaling.  Neither CC rOMVs nor Nsl-4 
rOMVs stimulated cells transfected with TLR4, though both Nsl-5 and Nsl-wt rOMVs produced 
a response (Figure 1B).  When cells transfected with mouse TLR4 (mTLR4) were incubated 
with rOMVs, CC, Nsl-4, and Nsl-5 rOMVs resulted in a moderate, but statistically significant 
(p<0.05), upregulation of signaling; mTLR4 transfected cells incubated with Nsl-wt rOMVs had 
high and statistically significant (p<0.001) upregulation of signaling (Figure 1C).  CC, Nsl-4, 
Nsl-5, and Nsl-wt rOMVs all stimulated cells transfected with TLR2 and mTLR2 (Figures D,E).  
The ability of all rOMV types to stimulate TLR2 suggests that TLR2 may play a role in shaping 
the immune response following rOMV vaccination.  While neither CC nor Nsl-4 rOMVs 
triggered human TLR4, CC, Nsl-4, and Nsl-5 rOMVs all stimulated murine TLR4.  Thus, further 
investigation is needed to ascertain whether mTLR4 signaling is critical to achieving a protective 
response from rOMVs.   
 
rOMVs stimulate macrophages in the absence of TLR4 
To further investigate the importance mTRL4 stimulation by rOMVs, TLR4 knockout (KO), 
TLR2 KO, and wild type (WT) murine macrophages were incubated with CC, Nsl-4, Nsl-5, and 
Nsl-wt rOMVs (Figures 2A-C). Six hours post incubation, the amount of TNF-α in supernatants 
was quantified via ELISA.  All 4 rOMV types resulted in statistically significant (p<0.05) TNF-
α production following incubation with TLR4 KO macrophages (Figure 2A).  Pure LPS did not 
significantly stimulate the TLR4 KO macrophages, confirming that LPS was not contributing to 
the response.  All rOMV types also stimulated TLR2 KO macrophages, possibly due to TLR4 
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activity (Figure 2B).  Pam3Cys did not stimulate TLR2 KO macrophages, confirming that the 
TNF-α produced was not due to TLR2 stimulation.  Especially high levels of TNF-α were 
produced following incubation of WT macrophages with rOMVs, suggesting that synergistic 
signaling due to concurrent TLR2 and TLR4 stimulation could be occurring. While the 
macrophage data indicated that TLR4 stimulation was not necessary for rOMVs to elicit TNF-α 
production in macrophages, it also confirmed that signaling was taking place through more than 
TLR2. 
 
 
Figure 2: TLR4 knock out (KO) (A), TLR2 KO (B), and TLR2/4 KO (C) macrophages were 
incubated with rOMVs for 6h, then supernatant collected and TNF-α measured. Error bars 
represent standard deviation of average.  Groups compared using ANOVA followed by 
comparisons to PBS using Dunnett’s test to account for multiple comparisons (* p<0.05). 
 
Nsl-4 and Nsl-5 rOMVs both lead to weight loss post vaccination 
BALB/c mice were vaccinated with M2e4xHet CC rOMVs, M2e4xHet Nsl-4 rOMVs, 
M2e4xHet Nsl-5 rOMVs, or PBS to determine whether the modified Nsl rOMVs were able to 
elicit high anti-M2e titers with low vaccination side effects.  Following vaccination, mice were 
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weighed daily to assess health following vaccination; mice that do not tolerate the vaccination 
well present with anorexia and weight loss.  Mice that were vaccinated with CC rOMVs 
displayed no weight loss and were not statistically different from mice that received a PBS 
injection (Figure 3A).  Mice that received Nsl-4 rOMVs had ~5% weight loss and took 2 days to 
recover back to the weight of mice that received only a PBS injection, though had minimal 
piloerection and displayed normal movement patterns (Figure 3A).  Mice that received Nsl-5 
rOMVs had ~10% weight loss and took 3 days to recover back to the weight of mice that 
received only a PBS injection (Figure 3A).   Additionally, mice that received Nsl-5 rOMVs 
exhibited piloerection post injection and developed swelling followed by scarring at the injection 
site.  The difference in weight loss between the Nsl-4 and Nsl-5 rOMVs demonstrates the 
reduction in inflammation that results between the pent-acylated and tetra-acylated lipid A 
structure, and suggests that Nsl-4 rOMVs are a safer platform than Nsl-5 rOMVs.  
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Figure 3: (A) Mice were weighed daily post vaccine prime. 
Dotted line equals titer of naïve sera. Error bars represent 
standard error of mean.  Groups compared with 2-way ANOVA 
followed by using Dunnett’s test to account for multiple 
comparisons to PBS (* p<0.05 PBS vs. Nsl-4; # p<0.05 PBS vs. 
Nsl-5).  (B,C) Total IgG (B) and IgG1 and IgG2a (C) anti-M2e 
titers were measured at 8 weeks post prime vaccination.  Error 
bars represent 95% confidence interval of geometric mean.  
Groups compared using Kruskal-Wallis test followed by 
multiple comparisons that were corrected by Tukey’s test. 
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CC, Nsl-4, and Nsl-5 rOMVs elicit high anti-M2e titers 
Blood was collected from CC, Nsl-4, and Nsl-5 vaccinated mice 8 weeks post prime vaccination 
and sera analyzed for anti-M2e antibodies.  CC, Nsl-4, and Nsl-5 rOMV vaccinated mice all 
produced high and statistically equivalent anti-M2e IgG titers (Figure 3B). Sera were further 
analyzed to compare IgG1 vs. IgG2a anti-M2e titers (Figure 3C).  All three mice had 
statistically equivalent IgG1 and IgG2a anti-M2e titers.  High levels of anti-M2e antibodies 
contribute to protection in influenza A challenge, suggesting that all three vaccines would offer 
good protection against influenza A challenge.   
 
CC, Nsl-4, and Nsl-5 rOMVs protect mice in lethal influenza A challenge 
BALB/c mice vaccinated with CC rOMVs, Nsl-4 rOMVs, Nsl-5 rOMVs, or PBS were 
challenged with a lethal dose of mouse adapted influenza strain A/Puerto Rice/8/1934 (H1N1) 
(PR8).  Mice vaccinated with CC, Nsl-4, and Nsl-5 rOMVs demonstrated 100% survival (5/5 per 
cohort) against PR8 challenge.  Additionally, all mice (5/5) vaccinated with PBS required 
euthanasia (Figure 4A).  There was no significant difference in weight loss between any of the 
rOMV vaccinated mice (Figure 4B).  Overall, the Nsl-4 and Nsl-5 rOMVs demonstrated that 
they were just as effective in protecting mice from influenza A challenge as CC rOMVs.  
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Figure 4: Mortality (A) and morbidity (B) of BALB/c mice following lethal dose (50 FFU) of 
influenza A/PR8.  Error bars (B) represent standard error of the mean. 
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Discussion 
Engineered E. coli Nissle strains containing only 4 or 5 acyl chains were able to successfully 
produce rOMVs containing the influenza antigen M2e4xHet.  Previously, E. coli Nissle 1917 
was engineered to have pent-acylated LPS through knock out of lpxM, though rOMVs from this 
modified Nissle strain were never tested in a challenge model4.  However, other strains of E. coli 
have been engineered through lpxM knock out and used in both therapeutic and prophylactic 
vaccine models. OMVs derived from E.coli strain W3110, a K-12 derived strain with an lpxM 
mutation, were used to deliver siDNA as a cancer therapeutic20.  Additionally, it was recently 
shown that E. coli strain JH8033, which lacks lpxM, could be further engineered to generate and 
display glycosylated rOMVs that protected against Francisella tularensis challenge21.  While 
these groups generated pent-acyltaed E. coli strains via knock out of solely lpxM, the strains used 
in this paper (apart from Nsl-wt) also had genes lpxT, eptA, and crcA knocked out.  Following 
the work produced by Needham et al, we decided to knock out these three genes, which all 
modify lipid A, to try and create Nissle strains with a more homogeneous lipid A profile22. 
Future work analyzing the LPS contained in Nsl-4 and Nsl-5 rOMVs using mass spectrometry 
will allow verification of the homogeneity of their LPS content.   
The Nsl-4 and Nsl-5 rOMVs were able to successfully elicit high anti-M2e titers and 
protect mice from influenza challenge, though they still led to more weight loss post vaccination 
than CC rOMVs.  Previously, rOMVs generated from E. coli Nissle 1917 were shown to have 
the advantage of eliciting a strong Th1 bias with elevated IgG2a:IgG1 antibody levels, even 
when used in BALB/c mice, a Th2 biased strain4.  However, while CC, Nsl-4, and Nsl-5 rOMV 
vaccines all elicited anti-M2e IgG2a titers above those of naïve sera, none of the vaccines 
produced anti-M2e IgG2a titers that were statistically elevated relative to anti-M2e IgG1 titers.  
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Thus, wild type LPS appears to be critical to generating elevated IgG2a titers.  Elevated IgG2a 
levels are only one component of a Th1 biased response, suggesting that further analysis of the 
cellular response to M2e4xHet rOMVs will provide a more nuanced view.   
CC, Nsl-4, and Nsl-5 rOMVs all had statistically equivalent pyrogenicity, as measured by 
the whole blood monocyte activation test. However, Nsl-5 rOMVs stimulated both murine and 
human TLR4, whereas Nsl-4 and CC rOMV stimulated only mTRL4. The similar responses 
elicited by CC and Nsl-4 rOMVs in not stimulating TRL4, but stimulating mTLR4 was expected, 
as the lipid A region is the portion of LPS that interacts with the CD14/MD-2 complex, and both 
CC and Nsl-4 contain lipid A with 4 acyl chains.  However, it was somewhat surprising that Nsl-
5 rOMVs stimulated human TLR4, despite having the same level of pyrogenicity as Nsl-4 and 
CC rOMVs; possibly, the additional stimulation of TLR4 was insignificant due to other pathogen 
recognition receptors (PRR) being stimulated.  It was also unexpected that CC and Nsl-4 rOMVs 
had the same level of pyrogenicity, despite Nsl-4 rOMVs containing the additional PAMPs 
flagellin and fimbrie.  It is possible that the differences in pyrogenicity between the Nsl-4, Nsl-5, 
and CC groups were too subtle to detect using the pyrogenicity assay, but that other endotoxin 
measurement methods, such as the rabbit pyrogens test, would yield different results23.  Overall, 
the low pyrogenicity of Nsl-4 and Nsl-5 rOMVs suggests that they are better vaccine candidates 
than Nsl-wt.   
The in vitro macrophage work confirmed the TLR work, showing that rOMVs stimulated 
more than just mTLR4.  Thus, while wild type mouse models are not ideal for testing rOMV 
efficacy, the macrophage data demonstrates that there is still potential for rOMVs to be 
sufficiently immunogenic for a human vaccine.  Future work using TLR4 knock out mice and 
transgenic human TLR4/MD-2 mice will further demonstrate the translational potential of 
 	  
	  
134 
rOMVs with LPS modifications24.  Additionally, it will be interesting to see if TLR4 knock out 
mice lose weight post Nsl-4 and Nsl-5 vaccination, as wild type mice did.  If it is specifically 
LPS stimulation of mTLR4 driving the inflammation and weight loss, then removal of mTLR4 
should ameliorate these side effects.  The macrophage data also indicated that just as mTLR4 
stimulation was not necessary to elicit TNF-α production from macrophages, TLR2 stimulation 
was also not necessary.  Future experiments using TLR2/4 knock out macrophages will 
demonstrate whether other PRRs are contributing to the immunogenicity of rOMVs.  Previously, 
Nissle rOMVs were shown to stimulate through TLR2, TLR4, and TLR5, and to a lesser extent, 
TLR92,4.  Thus, it is likely that Nsl-4 and Nsl-5 rOMVs should continue to stimulate even 
TLR2/4 KO macrophages, though CC rOMVs may see a significant drop in their stimulation 
potential.  In addition to work using murine macrophages, use of human-derived macrophages 
will allow species specific differences to be detected. As a whole, the macrophages responded 
similarly to all rOMVs tested; further work is needed to elucidate specific differences between 
the rOMV types.   
In conclusion, we demonstrate the ability to use serial gene knock out in E. coli strain 
Nissle 1917 to engineer strains with pent-acylated and tetra-acylated LPS.  These engineered 
Nissle strains were used to produce rOMVs displaying the influenza antigen M2e4xHet and 
successfully immunized mice against influenza, protecting them against a lethal PR8 challenge.  
While Nsl-4 and Nsl-5 rOMVs both led to weight loss in mice following vaccination, they had 
equivalent pyrogenicity to CC rOMVs in tests using human whole blood.   Though further work 
is needed to determine whether Nissle 1917 derived rOMVs offer any superior benefits to 
ClearColi® derived rOMVs, overall, the Nsl-4 rOMVs represent a viable adjuvant platform with 
many of the same benefits as CC rOMVs. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
Here, we demonstrate that rOMVs are a safe and viable adjuvant platform toward the 
development of a universal influenza vaccine.  Previously, while rOMVs had indicated some 
potential as a vaccine adjuvant, high levels of LPS limited their translation in to the clinic.  
Through the engineering of probiotic E. coli strain Nissle 1917 (Nsl) to produce LPS that was 
pent-acylated (Nsl-5) and tetra-acylated (Nsl-4) rather than hex-acylated, we were able to 
generate rOMVs with reduced toxicity.  Additionally, engineering a preexisting stain of E. coli, 
Clearcoli® (CC), to hypervesiculate, allowed production of rOMVs that contained only the LPS 
precursor lipid IVa.  Each of these detoxified E. coli strains were used to produce rOMVs that 
displayed the influenza antigen M2e4xHet. Vaccination with M2e4xHet rOMVs from all three 
detoxified strains resulted in complete survival of BALB/c mice against lethal influenza 
challenge.  Additionally, mice vaccinated with CC M2e4xHet rOMVs displayed complete 
survival against two different subtypes of influenza: H1N1 and H3N2.  The protection elicited by 
CC rOMVs lasted for at least 6 months post prime vaccination.  Single dose vaccination and 
using PLGA microparticles to encapsulate CC rOMVs was as effective as the prime/boost 
regimen.  Furthermore, when CC rOMVs were used to vaccinate ferrets, ferrets had a two log 
reduction in lung viral titers during human pdmH1N1 challenge vs. ferrets that received a mock 
vaccine.  While mice vaccinated with Nsl-4 and Nsl-5 rOMVs showed some side effects post 
vaccination, CC rOMVs were able to elicit these protective immune responses against influenza 
without causing excessive inflammation or weight loss following vaccination, further 
emphasizing their potential as a safe vaccine platform.  While significant progress has been made 
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on making rOMVs a translatable adjuvant platform, much work is left to be accomplished, 
especially in further understanding the mechanisms of rOMV efficacy, and in improving 
characterization to allow for better batch-to-batch assessment. 
 
Future direction 1: Determination of role of TLR4 in response to rOMVs 
One of the most necessary future steps in this work is to test the immune response to rOMVs in a 
mTLR4 knock out mouse strain.  Tetra-acylated LPS and lipid IVa both moderately stimulate 
mTLR4, but do not stimulate hTLR4.  While the knock out macrophage experiments prove that 
mTLR4 stimulation is not necessary to elicit cytokine production from macrophages, wild type 
macrophages certainly had stronger responses to rOMVs than TLR4 knockout macrophages.  At 
the time of the writing of this Disseration, mTLR4 knockout mice are being bred, which will 
allow the efficacy of rOMVs to be assessed in a model where mTLR4 does not contribute to any 
signaling.  One downside is that the TLR4 knock out mouse is on a B6 background, which is a 
naturally Th1 biased mouse strain.  Thus, the rOMVs may perform better in terms of immune 
bias in this strain than in an mTLR4 knock out BALB/c strain.  In addition to the TLR4 knock 
out strain, several years ago, a humanized mouse model was developed that contains human 
TLR4 and MD2.  Unfortunately, this strain is hard to access and also is on the B6 background.  
In addition to the mouse work, further characterization of how ferrets respond to lipid IVa and 
LPS with lipid A modifications is necessary so that the relevance of the ferret model can be 
better assessed.  It is well established that ferrets are an excellent model for studying influenza 
and influenza vaccines; however, it is unknown how good of a model they are for studying 
inflammation due to LPS variants.  Pyrogenicity of rOMVs in humans was assessed using the 
whole blood pyrogenicity test, which requires a pair of anti IL-1β antibodies for use in an ELISA 
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to monitor inflammation.  Anti IL-1β antibody pairs do not exist for ferrets, but it is possible that 
ferret IL-1β might cross-react with anti IL-1β pairs intended for other species.  It might also be 
possible to instead run qPCR on ferret monocytes incubated with rOMVs and look for 
upregulation in mRNA of inflammatory cytokines.  Overall, determining the impact of mTLR4 
on the response to rOMVs is critical for assessing their potential for translation to humans. 
 
Future direction 2: Further exploration of E. coli Nissle 1917 derived rOMVs with tetra-
acylated LPS 
Nissle 1917 was engineered through a series of genetic knock outs to produce tetra-acylated 
LPS.  However, mass spectrometry is needed to analyze the LPS contained in Nsl-4 rOMVs and 
determine (1.) whether it is in fact tetra-acylated and (2.) how homogenous the LPS structure is.  
The mice that received Nsl-4 rOMVs still lost weight relative to mice that received only PBS and 
mice that received CC rOMV injections.  Though the mice that received Nsl-4 rOMVs did not 
show outward adverse effects, the weight loss indicates that there could be biocompatibility 
concerns.   Histology of the injection site at different time points post injection will help to assess 
the level of inflammation occurring.  Additionally, including an injection of alum as a control 
will help to determine how the inflammation from Nsl-4 rOMVs compares to that from a 
standard vaccine adjuvant.  As mentioned above, it is important to determine the role that 
mTLR4 contributes to rOMV immunogenicity.  It is possible that no weight loss would be seen 
in a TLR4 knockout mouse.  The TLR data indicates that Nsl rOMVs contain TLR9, TLR5, and 
TLR2 agonists.  Therefore, in addition to TLR4 knock out mice, it would be useful to ultimately 
test rOMVs in other knockout strains to better understand the mechanisms driving the response.  
Additionally, using MyD88 knock out mice would help to determine whether the bulk of the 
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response was in fact primarily TLR driven.  It is quite possible that inflammasomes and other 
PRRs are contributing to the response.  While theoretically Nsl-4 rOMVs should provide a more 
complex—and perhaps also more efficacious—stimulation of the innate immune system than CC 
rOMVs, which lack some of the PAMPS that Nsl-4 rOMVs contain, so far CC rOMVs appear to 
be the superior vaccine platform with respect to safety profile. 
 
Future direction 3:  Improved characterization of rOMVs 
The scope of the current thesis centered on the detoxification of rOMVs and improving their 
safety profile while maintaining efficacy.  However, for rOMVs to become a viable platform, 
improvements need to be made to their characterization: amount of antigen, distribution of 
antigen on rOMVs, concentration of rOMVs in a sample, and protein content within the lumen of 
rOMVs are all either difficult to determine, or are unknown.  Currently, the amount of antigen 
present on rOMVs is estimated using a semi-quantitiative Western Blot. While Western Blots 
can give a rough estimate of antigen content, they are not nearly as accurate as an ELISA.  By 
using anti-M2e antibodies and biotinylated anti-His antibodies, it may be possible to develop a 
sandwich ELISA that provides a more accurate measure of total M2e4xHet content in an rOMV 
preparation.  The standard curve would be generated from His-purified M2e4xHet, using a BCA 
assay to determine its concentration.  The second great unknown in rOMVs is how ClyA-antigen 
is distributed on the rOMV surface.  Previous papers have published cryo-TEM images that 
clearly show ClyA dimerizing into pore like structures on OMV surfaces; however, no cyro-
TEM images exist of rOMVs that display ClyA-M2e4xHet or ClyA-GFP.  While we have many 
TEM pictures of ClyA-M2e4xHet rOMVs, the greater resolution of cryo-TEM, coupled with 
immunohistochemistry to label the antigens with gold dots, is needed to get a sense for the 
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distribution of ClyA-antigens on the rOMV surface.  It is possible that different antigens result in 
different distributions on the rOMV surface.  For example, Western Blot data indicates that there 
is a higher concentration of antigen in M2e4xHet rOMVs than in ClyA-GFP rOMVs.  Do the 
ClyA-M2e4xHet rOMVs in fact contain more ClyA-M2e4xHet antigen per rOMV? Do all 
rOMVs contain about the same amount of ClyA-antigen, or does the amount per rOMV vary 
greatly?  In addition to these questions, it is unknown whether the distribution pattern of ClyA-
antigen on rOMV surfaces is strain specific.  Engineering the LPS will likely impact the 
properties of the bacterial membrane, so it would not be surprising if it also impacted the 
distribution of ClyA.  Finally, a simple way to measure the concentration of rOMVs in a 
preparation—not just the total protein concentration in the preparation—is necessary.  
Instruments, such as the Nanosight, may be useful for CC rOMVs; however, rOMVs derived 
from Nissle contain fragments of flagella, making rOMV concentration difficult to determine 
due to the highly polydispersed nature of the solution (flagella fragments are long and cylindrical 
whereas rOMVs are spherical).  Currently, when injecting rOVMs, the total number of rOMVs is 
unknown.  Finally, rOMVs remain a black box in terms of their content. Previous papers have 
found that rOMVs contain peptidoglycan fragments, DNA fragments, misfolded proteins, etc.; 
however, measuring all of these components on each rOMV preparation is currently impractical 
due to time and financial constraints.  However, a better understanding of what is located within 
the interior space of rOMVs, and how variable that content is from batch to batch will be 
important to bring rOMVs to market.  Thus, though we have seen consistent responses in mice to 
our CC M2e4xHet rOMVs, improvements to rOMVs characterization will allow for more 
confidence when dosing and for more nuanced conclusions to be drawn, paving the way for 
translation into the clinic.  
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Final thoughts 
The detoxified rOMV platform holds much promise and there certainly are many more aspects to 
explore than the three future directions listed above.  Studying the trafficking of rOMVs using 
confocal microscopy, optimizing the M2e antigenic sequence, exploring antigens from other 
pathogens, determining the adjuvanticity of ClyA-M2e4xHet, studying the cellular response to 
vaccination using cytotoxic T cell killing assays and adoptive transfer, exploring alternate 
delivery routes, and determining the impact on rOMV production of different growing conditions 
are all interesting questions that could be explored.  It has been exciting to work on a project 
with such translational potential, and who knows, maybe in twenty years I’ll walk into a health 
center for a flu vaccine and find that it’s formulated with rOMVs.  Overall, detoxified rOMVs 
have demonstrated great potential as a platform for influenza vaccines and could potentially be a 
great platform for other antigens as well.   
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APPENDIX I 
Supplemental Information for Chapter 2 
 
Sequences for expressed M2e peptides 
Three codon optimized M2e-based sequences were expressed in E. coli and used to produce 
recombinant OMVs.  
 
M2e1xS 
 
Peptide:SLLTEVETPIRNEWGSRSNDSSD  
 
Entire nucleotide sequence inserted into pBAD plasmid:  
tctagaatgAGCCTGCTGACCGAAGTTGAAACCCCGATTCGTAATGAATGGGGTAGCCGT
AGCAATGATAGCAGCGATcatcaccatcaccatcactaaaagctt 
	  
	  
M2e1xC 
 
Peptide:SLLTEVETPIRNEWGCRCNDSSD  
 
Entire nucleotide sequence inserted into pBAD plasmid: 
tctagaAGCCTGCTGACCGAAGTTGAAACCCCGATTCGTAATGAATGGGGTTGTCGTTG
TAATGATAGCAGTGATcatcaccatcaccatcactaaaagcttgg 
 
 
 
M2e4xHet 
	  
Peptide:SLLTEVETPIRNEWGSRSNDSSDgggsgggSLLTEVETPTRSEWESRSSDSSDgggsgg
gSLLTEVETPTRNEWESRSSDSSDgggsgggSLLTEVETLTRNGWGSRSSDSSD  
 
Entire nucleotide sequence inserted into pBAD plasmid:  
tctagaAGCCTGCTGACCGAAGTTGAAACCCCGATTCGTAATGAATGGGGTAGCCGTAG
CAATGATAGCAGTGATGGCGGTGGTAGCGGTGGTGGCTCACTGCTGACAGAGGTGG
AAACACCGACCCGTAGCGAATGGGAAAGCCGTAGTAGCGATAGCTCAGATGGCGGT
GGTAGCGGTGGTGGCAGTCTGCTGACGGAAGTAGAGACTCCGACCCGCAATGAGTG
GGAAAGTCGTTCAAGCGATTCATCAGATGGCGGTGGTAGCGGTGGTGGCAGCCTGC
TGACTGAGGTCGAGACACTGACACGCAATGGTTGGGGTTCACGTAGCTCTGATAGC
AGCGATcatcaccatcaccatcactaaaagctt 
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HEK293 stimulation via M2e4xHet-OMVs 
TLR5 stimulation via M2e4xHet-OMVs was confirmed by using HEK293 cells in addition to 
HEK293 TLR5 KD cells 
 
 
 
Figure S1: HEK293 cells transformed with CMV-β-
galactosidase and 5xNF-κB-luciferase were stimulated with 
4xHetM2e-OMVs (10 ng/mL), positive control (flagellin), or 
media.  Addition of M2e4xHet-OMVs resulted in significant 
increase in luciferase production vs. media alone (* p<0.0001). 
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APPENDIX II 
Supplemental Information for Chapter 3 
Table S1: Primers used for PCR 
Primer Sequence (5’- 3’) Source 
gutQ-F GTCGATAAGCTGATTACCGACGC Mamat 20151 
gutQ-R GTGAAACTATTCGTCAGGCACTGG Mamat 20151 
nlpI-F ATTTACGCCGCGCATGTGTTTAG This paper 
nlpI-R AGGGCCGTATCCGTCTGAGC This paper 
 
1. Mamat, U, Wilke, K, Bramhill, D, Schromm, AB, Lindner, B, Kohl, TA, et al. (2015). 
Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. 
Microb. Cell Fact. 14: 1–15. 
 
 
 
	  
Figure S1: (a) Western blot of rOMVs expressing ClyA-GFP developed using anti-GFP 
antibody.  Lane 1: ClyA-GFP CC rOMVs (2 µg), lane 2: ClyA-GFP BL21 rOMVs (2 
µg), lane 3: ClyA-GFP purified protein (0.125 µg). (b) Western blot of rOMVs 
expressing influenza-based antigen ClyA-M2e4xHet developed using anti-His tag 
antibody.  Lane 1: ClyA-M2e4xHet CC rOMVs (1 µg), lane 2: ClyA-M2e4xHet Nsl 
rOMVs (1 µg), lane 3: ClyA-M2e4xHet purified protein (0.2 µg).  Both blots developed 
using chemiluminescence and imaged with Bio-Rad ChemiDoc Touch Imaging System 
(Bio-Rad, Hercules, CA). 
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Figure S2: PRR signaling in response to rOMVs. (a) HEK-BlueTM KD-TLR5 cells were 
transfected with human TLR2, 3, 7, and 9, then stimulated with CC, Nsl, and BL21 
rOMVs (100 ng/mL). (b) HEK-BlueTM KD-TLR5 cells were transfected with murine 
TLR2, 3, 9, and 11, then stimulated with CC, Nsl, and BL21 rOMVs (100 ng/mL). (c) 
HEK-293 cells were transfected with a 5xNF-kβ-luciferase reporter plasmid and TLR5, 
then stimulated with CC, Nsl, and BL21 rOMVs (100 ng/mL).  (d, e) HEK-293 BlueTM 
murine NOD1 (d) and NOD2 (e) reporter cells were stimulated with CC, Nsl, and BL21 
rOMVs (100 ng/mL). Graphs analyzed using ANOVA followed by multiple 
comparisons to stimulation caused by media using Dunnett method of correction,  * 
p<0.01.  Error bars represent mean + SD (n=4). 
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S3: BMDCs were isolated from BALB/c and C57BL/6 mice, then stimulated with CC rOMVs 
(100 ng/mL), Nsl rOMVs (100 ng/mL), LPS (100 ng/mL) or PBS.  Media was collected 48h post 
stimulation and analyzed for IL-10 (a), IL-12p70 (b), type I IFN (c), IL-6 (d), and TNF-α (e). 
Error bars represent standard deviation. Samples analyzed via ANOVA followed by Holm 
multiple comparison test * p<0.05 (n=3).   
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Figure S4: (a) Day 3 post influenza exposure, ferrets were assessed for viral titers.  Groups 
analyzed with 2-way ANOVA, followed by multiple comparisons to mock CC rOMV using 
Bonferroni method of correction (n=3) ** p<0.01. (b,c) Weight loss (b) and temperature (c) were 
monitored in ferrets post influenza (pdmH1N1) exposure.   
 
 
Na
sa
l w
as
h
Na
sa
l tu
rb
ina
te
Tr
ac
he
a
Lu
ng
0
2
4
6
8
Vi
ra
l t
ite
r (
lo
g 1
0 
EI
D 5
0/m
L 
or
 lo
g 1
0E
ID
50
/g
) )
M2e4xHet CC rOMV
Fluvirin
Mock CC rOMV
p<0.01,**
0 5 10 15 20
70
80
90
100
110
Days post pdmH1N1 challenge
%
 O
rig
in
al
 w
ei
gh
t
0 5 10 15
36
38
40
42
Days post pdmH1N1 challenge
Fe
rr
et
 te
m
pe
ra
tu
re
 (°
C)
M2e4xHet  CC rOMV
Fluvirin
Mock CC rOMV
M2e4xHet  CC rOMV
Fluvirin
Mock CC rOMV
a b c
